Treatment of Hepatitis C in Chronic Kidney Disease. KDIGO 2022 update

Project Summary Title and Description

Title
Treatment of Hepatitis C in Chronic Kidney Disease. KDIGO 2022 update
Description
Update of KDIGO 2018 CPG, focused on DAA treatments in specific CKD populations (Guideline 2), donor-positive to recipient-negative transplantation (Guideline 4), and HCV-related glomerular disease (Guideline 5)
Attribution
Kidney Disease: Improving Global Outcomes (KDIGO)
Authors of Report
Ethan Balk (Brown SPH) Craig Gordon (Tufts MC) Gaelen Adam (Brown SPH)
Methodology description
Systematic Review
PROSPERO
N/A
DOI
N/A
Notes
Literature search through 1 February 2022. PubMed, Embase, Cochrane, CINAHL, ClinicalTrials.gov and major conference presentation 2019, 2020, and 2021. Guideline 2 restricted to studies that reported for specific CKD populations (CKD G4-G5ND, CKD 5D, and transplant) and specific DAA regimens. Allowed non-specified DAAs only if comparison with no DAA treatment (for long-term outcomes). Guideline 4 restricted to studies that reported specifically on kidney transplantation with HCV-positive donors to HCV-negative recipients (D+/R-). Guideline 5 included any treatment of HCV-related glomerulonephritis or cryoglobulinemia. Data entered prospectively into SRDRplus. Guideline will be available at https://kdigo.org/guidelines/. Systematic reviews will likely be published in Kidney International (together with the guideline).
Funding Source
KDIGO

Key Questions

1. Evidence map (abstract phase)
2. GL 2, 4, 5 (Extraction)

Associated Extraction Forms

Associated Studies (each link opens a new tab)

TitleAuthorsYear
Efficacy and safety of Glecaprevir/Pibrentasvir in patients with metabolic syndrome and HCV infection: An integrated analysisAghemo, A.; Baumgarten, A.; DeLedinghen, V.; Jacobson, I.; Lee, S. S.; Saab, S.; Kleine, H.; De Michina, A.; Lei, Y.; Collins, C.; Craxi, A.2018
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney diseaseAglitti, A.; Caruso, R.; Calvanese, G.; Di Siervi, P.; Tripodi, M. F.; Masarone, M.; Persico, M.2019
Persistence of circulating cryoglobulins and related symptoms after hepatitis c virus eradication in patients with mixed cryoglobulin syndromeBassoli, C. R.; Oreni, L.; Sollima, S.; Saccardo, F.; Sebastiani, M.; Vacchi, C.; Mazzaro, C.; Zani, R.; Ferri, C.; Zignego, A. L.; Monti, G.; Brancaccio, G.; Gentile, I.; Masarone, M.; Gabiati, C.; Pontali, E.; Castelnovo, L.; Messina, V.; Galli, M.2019
Long-term immunological and clinical impact of HCVeradication with direct acting antivirals in patients with HCV-associated cryoglobulinemia vasculitisBonacci, M.; Lens, S.; Maro, Z.; Rodriguez-Tajes, S.; Bartres, C.; Ramos-Casals, M.; Hernndez-Rodrguez, J.; Forns, X.2018
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 45 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trialBruchfeld, A.; Roth, D.; Martin, P.; Nelson, D. R.; Pol, S.; Londoo, M. C.; Monsour, H.; Silva, M.; Hwang, P.; Arduino, J. M.; Robertson, M.; Nguyen, B. Y.; Wahl, J.; Barr, E.; Greaves, W.2017
Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/minNazario, H. E.; Ndungu, M.; Modi, A. A.2016
Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney TransplantationKamar, N.; Marion, O.; Rostaing, L.; Cointault, O.; Ribes, D.; Lavayssire, L.; Esposito, L.; Del Bello, A.; Mtivier, S.; Barange, K.; Izopet, J.; Alric, L.2016
Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral AgentsSawinski, D.; Kaur, N.; Ajeti, A.; Trofe-Clark, J.; Lim, M.; Bleicher, M.; Goral, S.; Forde, K. A.; Bloom, R. D.2016
Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective studyBhamidimarri, K. R.; Ladino, M.; Pedraza, F.; Guerra, G.; Mattiazzi, A.; Chen, L.; Ciancio, G.; Kupin, W.; Martin, P.; Burke, G.; Roth, D.2017
Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failureDumortier, J.; Bailly, F.; Pageaux, G. P.; Vallet-Pichard, A.; Radenne, S.; Habersetzer, F.; Gagnieu, M. C.; Grang, J. D.; Minello, A.; Guillaud, O.; Kamar, N.; Alric, L.; Leroy, V.2017
Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal functionSaxena, V.; Koraishy, F. M.; Sise, M. E.; Lim, J. K.; Schmidt, M.; Chung, R. T.; Liapakis, A.; Nelson, D. R.; Fried, M. W.; Terrault, N. A.2016
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal DiseasePockros, P. J.; Reddy, K. R.; Mantry, P. S.; Cohen, E.; Bennett, M.; Sulkowski, M. S.; Bernstein, D. E.; Cohen, D. E.; Shulman, N. S.; Wang, D.; Khatri, A.; Abunimeh, M.; Podsadecki, T.; Lawitz, E.2016
Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysisToyoda, H.; Kumada, T.; Tada, T.; Takaguchi, K.; Ishikawa, T.; Tsuji, K.; Zeniya, M.; Iio, E.; Tanaka, Y.2016
Ledipasvir/sofosbuvir for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 hcv infectionColombo, M.; Aghemo, A.; Liu, L.; Hyland, R.; Yun, C.; Brainard, D.; McHutchison, J.; Bourliere, M.; Peck-Radosavljevic, M.; Manns, M.; et al.2016
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized TrialColombo, M.; Aghemo, A.; Liu, H.; Zhang, J.; Dvory-Sobol, H.; Hyland, R.; Yun, C.; Massetto, B.; Brainard, D. M.; McHutchison, J. G.; Bourlire, M.; Peck-Radosavljevic, M.; Manns, M.; Pol, S.2017
Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on HemodialysisMiyazaki, R.; Miyagi, K.2016
Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis CSuda, G.; Kudo, M.; Nagasaka, A.; Furuya, K.; Yamamoto, Y.; Kobayashi, T.; Shinada, K.; Tateyama, M.; Konno, J.; Tsukuda, Y.; Yamasaki, K.; Kimura, M.; Umemura, M.; Izumi, T.; Tsunematsu, S.; Sato, F.; Terashita, K.; Nakai, M.; Horimoto, H.; Sho, T.; Natsuizaka, M.; Morikawa, K.; Ogawa, K.; Sakamoto, N.2016
Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in JapanSuda, G.; Furusyo, N.; Toyoda, H.; Kawakami, Y.; Ikeda, H.; Suzuki, M.; Arataki, K.; Mori, N.; Tsuji, K.; Katamura, Y.; Takaguchi, K.; Ishikawa, T.; Tsuji, K.; Shimada, N.; Hiraoka, A.; Yamsaki, S.; Nakai, M.; Sho, T.; Morikawa, K.; Ogawa, K.; Kudo, M.; Nagasaka, A.; Furuya, K.; Yamamoto, Y.; Kato, K.; Ueno, Y.; Iio, E.; Tanaka, Y.; Kurosaki, M.; Kumada, T.; Chayama, K.; Sakamoto, N.2018
Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney diseaseMorisawa, N.; Koshima, Y.; Satoh, J. I.; Maruyama, Y.; Kuriyama, S.; Yokoo, T.; Amemiya, M.2017
Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunctionNakamura, Y.; Imamura, M.; Kawakami, Y.; Teraoka, Y.; Daijo, K.; Honda, F.; Morio, K.; Kobayashi, T.; Nakahara, T.; Nagaoki, Y.; Kawaoka, T.; Tsuge, M.; Hiramatsu, A.; Aikata, H.; Hayes, C. N.; Miki, D.; Ochi, H.; Chayama, K.2017
Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experienceAbd-Elsalam, S.; Abo-Amer, Y. E.; El-Abgeegy, M.; Elshweikh, S. A.; Elsergany, H. F.; Ahmed, R.; Elkadeem, M.; Hawash, N.; Soliman, S.; Badawi, R.; Elguindy, A. M. A.; Soliman, M. Y.; Mohmed, A. A.; Mansour, L.2020
Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective studyAkhil, M. S.; Kirushnan, B.; Martin, M.; Arumugam, K.; Ganesh Prasad, N. K.; Ravichandran, R.2018
Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patientsAbad, S.; Vega, A.; Rincn, D.; Hernndez, E.; Mrida, E.; Macas, N.; Muoz, R.; Milla, M.; Luo, J.; Lpez-Gmez, J. M.2017
Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4Abad, S.; Vega, A.; Hernndez, E.; Mrida, E.; de Sequera, P.; Albalate, M.; Macas, N.; Milla, M.; Lpez-Gmez, J. M.2017
Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based RegimenAgarwal, S. K.; Bagchi, S.; Yadav, R. K.2017
Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center studyAgarwal, S. K.; Bhowmik, D.; Mahajan, S.; Bagchi, S.2016
Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center ExperienceAggarwal, A.; Yoo, E. R.; Perumpail, R. B.; Cholankeril, G.; Kumari, R.; Daugherty, T. J.; Lapasaran, A. S.; Ahmed, A.2017
Effectiveness and safety of sofosbuvir/ledipasvirribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experienceAkin, M.; Buldukoglu, O. C.; Adanir, H.; Suleymanlar, I.; Dincer, D.; Yildirim, B.2018
Eradication of hepatitis C virus infection in kidney transplant recipients using direct-acting antiviral therapy: Qatar experienceAlkadi, M. M.; Abuhelaiqa, E. A.; Elshirbeny, M. F.; Hamdi, A. F.; Fituri, O. M.; Asim, M.; Alkaabi, S. R.; Derbala, M. F.; Jarman, M. E.; Ashour, A. M.; Nauman, A.; Al Maslamani, Y. K.; Butt, A. A.; Al-Malki, H. A.2020
Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effectiveAlric, L.; Ollivier-Hourmand, I.; Brard, E.; Hillaire, S.; Guillaume, M.; Vallet-Pichard, A.; Bernard-Chabert, B.; Loustaud-Ratti, V.; Bourlire, M.; de Ledinghen, V.; Fouchard-Hubert, I.; Canva, V.; Minello, A.; Nguyen-Khac, E.; Leroy, V.; Saadoun, D.; Trias, D.; Pol, S.; Kamar, N.2018
Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney diseaseArai, T.; Atsukawa, M.; Tsubota, A.; Ikegami, T.; Shimada, N.; Kato, K.; Abe, H.; Okubo, T.; Itokawa, N.; Kondo, C.; Mikami, S.; Asano, T.; Chuganji, Y.; Matsuzaki, Y.; Toyoda, H.; Kumada, T.; Iio, E.; Tanaka, Y.; Iwakiri, K.2018
Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter studyAtsukawa, M.; Tsubota, A.; Toyoda, H.; Takaguchi, K.; Kondo, C.; Okubo, T.; Hiraoka, A.; Michitaka, K.; Fujioka, S.; Uojima, H.; Watanabe, T.; Ikeda, H.; Asano, T.; Ishikawa, T.; Matsumoto, Y.; Abe, H.; Kato, K.; Tsuji, K.; Ogawa, C.; Shimada, N.; Iio, E.; Mikami, S.; Tanaka, Y.; Kumada, T.; Iwakiri, K.2019
Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis CAtsukawa, M.; Tsubota, A.; Koushima, Y.; Ikegami, T.; Watanabe, K.; Shimada, N.; Sato, S.; Kato, K.; Abe, H.; Okubo, T.; Arai, T.; Itokawa, N.; Kondo, C.; Mikami, S.; Asano, T.; Chuganji, Y.; Matsuzaki, Y.; Iwakiri, K.2017
The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter studyAtsukawa, M.; Tsubota, A.; Toyoda, H.; Takaguchi, K.; Nakamuta, M.; Watanabe, T.; Michitaka, K.; Ikegami, T.; Nozaki, A.; Uojima, H.; Fukunishi, S.; Genda, T.; Abe, H.; Hotta, N.; Tsuji, K.; Ogawa, C.; Tachi, Y.; Shima, T.; Shimada, N.; Kondo, C.; Akahane, T.; Aizawa, Y.; Tanaka, Y.; Kumada, T.; Iwakiri, K.2019
The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomesAxelrod, D. A.; Schnitzler, M. A.; Alhamad, T.; Gordon, F.; Bloom, R. D.; Hess, G. P.; Xiao, H.; Nazzal, M.; Segev, D. L.; Dharnidharka, V. R.; Naik, A. S.; Lam, N. N.; Ouseph, R.; Kasiske, B. L.; Durand, C. M.; Lentine, K. L.2018
DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation settingBeinhardt, S.; Al Zoairy, R.; Ferenci, P.; Kozbial, K.; Freissmuth, C.; Stern, R.; Stttermayer, A. F.; Stauber, R.; Strasser, M.; Zoller, H.; Watschinger, B.; Schmidt, A.; Trauner, M.; Hofer, H.; Maieron, A.2016
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimensBoglione, L.; Cusato, J.; Pinna, S. M.; De Nicol, A.; Cariti, G.; Di Perri, G.; D'Avolio, A.2018
Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic CureBonacci, M.; Lens, S.; Mario, Z.; Londoo, M. C.; Rodriguez-Tajes, S.; Snchez-Tapias, J. M.; Ramos-Casals, M.; Hernndez-Rodrguez, J.; Forns, X.2018
Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting AntiviralsBonacci, M.; Lens, S.; Londoo, M. C.; Mario, Z.; Cid, M. C.; Ramos-Casals, M.; Snchez-Tapias, J. M.; Forns, X.; Hernndez-Rodrguez, J.2017
Sofosbuvir/velpatasvir for 12weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysisBorgia, S. M.; Dearden, J.; Yoshida, E. M.; Shafran, S. D.; Brown, A.; Ben-Ari, Z.; Cramp, M. E.; Cooper, C.; Foxton, M.; Rodriguez, C. F.; Esteban, R.; Hyland, R.; Lu, S.; Kirby, B. J.; Meng, A.; Markova, S.; Dvory-Sobol, H.; Osinusi, A. O.; Bruck, R.; Ampuero, J.; Ryder, S. D.; Agarwal, K.; Fox, R.; Shaw, D.; Haider, S.; Willems, B.; Lurie, Y.; Calleja, J. L.; Gane, E. J.2019
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trialBruchfeld, A.; Roth, D.; Martin, P.; Nelson, D. R.; Pol, S.; Londoo, M. C.; Monsour, H., Jr.; Silva, M.; Hwang, P.; Arduino, J. M.; Robertson, M.; Nguyen, B. Y.; Wahl, J.; Barr, E.; Greaves, W.2017
Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVESButt, A. A.; Yan, P.; Shaikh, O. S.; Chung, R. T.; Sherman, K. E.2016
Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES studyButt, A. A.; Ren, Y.; Puenpatom, A.; Arduino, J. M.; Kumar, R.; Abou-Samra, A. B.2018
Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir RegimenButt, N.; Abbasi, A.; Ali Khan, M.; Ali, M.; Mahesar, G. B.; Haleem, F.; Manan, A.
Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: final results of the C-SURFER phase 3 studyBarr, E.; Roth, D.; Bruchfeld, A.; Martin, P.; Nelson, D. R.; Silva, M.; Monsour, H.; Alric, L.; Wan, S.; Jackson, B.; et al.2016
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trialBruchfeld, A.; Roth, D.; Martin, P.; Nelson, D. R.; Pol, S.; Londoo, M. C.; Monsour, H.; Silva, M.; Hwang, P.; Arduino, J. M.; et al.2017
Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemiaAdinolfi, L. E.; Utili, R.; Zampino, R.; Ragone, E.; Mormone, G.; Ruggiero, G.1997
Treatment uptake and real world effectiveness of sofosbuvir/ ledipasvir and paritaprevir/ritonavir/ombitasvir/dasabuvir among HCV-infected persons with chronic kidney diseaseAlkadi, M. M.; Ren, Y.; Puenpatom, A.; Kumar, R.; Arduino, J. M.; Abou-Samra, A. B.; Butt, A. A.2017
Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot StudyGragnani, L.; Piluso, A.; Urraro, T.; Fabbrizzi, A.; Fognani, E.; Petraccia, L.; Genovesi, A.; Giubilei, L.; Ranieri, J.; Stasi, C.; Monti, M.; Zignego, A. L.2017
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemiaGragnani, L.; Visentini, M.; Fognani, E.; Urraro, T.; De Santis, A.; Petraccia, L.; Perez, M.; Ceccotti, G.; Colantuono, S.; Mitrevski, M.; Stasi, C.; Del Padre, M.; Monti, M.; Gianni, E.; Pulsoni, A.; Fiorilli, M.; Casato, M.; Zignego, A. L.2016
Use of HCV+ Donors Does Not Affect HCV Clearance With Directly Acting Antiviral Therapy But Shortens the Wait Time to Kidney TransplantationSawinski, D.; Patel, N.; Appolo, B.; Bloom, R.2017
Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant RecipientsEisenberger, U.; Guberina, H.; Willuweit, K.; Bienholz, A.; Kribben, A.; Gerken, G.; Witzke, O.; Herzer, K.2017
Real-world use of elbasvir/grazoprevir and outcomes in patients with chronic hepatitis C: retrospective data analyses from the TRIO NetworkBacon, B.; Curry, M.; Dieterich, D.; Flamm, S.; Kowdley, K.; Milligan, S.; Nwankwo, C.; Tsai, N.; Younossi, Z.; Afdhal, N.2017
Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients With Directly Acting Antiviral AgentsLubetzky, M.; Chun, S.; Joelson, A.; Coco, M.; Kamal, L.; Ajaimy, M.; Gaglio, P.; Akalin, E.; De Boccardo, G.2017
Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis CFernndez, I.; Muoz-Gmez, R.; Pascasio, J. M.; Baliellas, C.; Polanco, N.; Esforzado, N.; Arias, A.; Prieto, M.; Castells, L.; Cuervas-Mons, V.; Hernndez, O.; Crespo, J.; Calleja, J. L.; Forns, X.; Londoo, M. C.2017
Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virusMorales, A. L.; Liriano-Ward, L.; Tierney, A.; Sang, M.; Lalos, A.; Hassan, M.; Nair, V.; Schiano, T.; Satoskar, R.; Smith, C.2017
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET studySaxena, V.; Khungar, V.; Verna, E. C.; Levitsky, J.; Brown, R. S., Jr.; Hassan, M. A.; Sulkowski, M. S.; O'Leary, J. G.; Koraishy, F.; Galati, J. S.; Kuo, A. A.; Vainorius, M.; Akushevich, L.; Nelson, D. R.; Fried, M. W.; Terrault, N.; Reddy, K. R.2017
Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipientsTaneja, S.; Duseja, A.; De, A.; Kumar, V.; Ramachandran, R.; Sharma, A.; Dhiman, R. K.; Gupta, K. L.; Chawla, Y.2018
Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis populationBasu, P.; Sinki, R.; Shah, N.; Farhat, S.; Mittimani, K.; Atluri, S.2013
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal ImpairmentGane, E.; Lawitz, E.; Pugatch, D.; Papatheodoridis, G.; Bru, N.; Brown, A.; Pol, S.; Leroy, V.; Persico, M.; Moreno, C.; Colombo, M.; Yoshida, E. M.; Nelson, D. R.; Collins, C.; Lei, Y.; Kosloski, M.; Mensa, F. J.2017
Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population target C trial: a placebo randomized control clinical trialBasu, P.; Shah, N.; Siriki, R.; Rahaman, M.; Farhat, S.2013
Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC studySaadoun, D.; Thibault, V.; Si Ahmed, S. N.; Alric, L.; Mallet, M.; Guillaud, C.; Izzedine, H.; Plaisier, A.; Fontaine, H.; Costopoulos, M.; Le Garff-Tavernier, M.; Hezode, C.; Pol, S.; Musset, L.; Poynard, T.; Cacoub, P.2016
Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-a placebo randomized control clinical trialBasu, P. P.; Shah, N. J.; Ashfique; Farhat, S.; Siriki, R.2014
C-surfer: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis c virus genotype 1 infection and chronic kidney diseaseBruchfeld, A.; Roth, D.; Nelson, D.; Liapakis, A. M.; Silva, M.; Monsour, H.; Martin, P.; Pol, S.; Londono, M. C.; Hassanein, T.; et al.2015
Elbasvir/Grazoprevir (EBR/GZR) treatment of Hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER studyBruchfeld, A.; Roth, D.; Martin, P.; Nelson, D.; Stanislas, P.; Londono, M. C.; Viviani, D.; Wan, S.; Arduino, J.; Robertson, M.; et al.2016
Direct-acting Antivirals for the Treatment of Kidney Transplant Patients With Chronic Hepatitis C Virus Infection in Spain: A Long-term Prospective Observational StudyGonzalez-Corvillo, C.; Beneyto, I.; Sanchez-Fructuoso, A.; Perell, M.; Alonso, A.; Mazuecos, A.; Jiminez, C.; Zarraga, S.; Paul, J.; Lauzurica, R.; Hernandez, D.; Guirado, L.; Franco, A.; Ruiz, J. C.; Llorente, S.; Crespo, M.; Rodriguez-Benot, A.; de Gracia Guindo, M. D. C.; Diaz-Corte, C.; Gentil, M2019
Direct-acting Antiviral Agents in Hepatitis C Virus-infected Renal Allograft Recipients: Treatment and Outcome Experience from Single CenterPrasad, N.; Patel, M. R.; Pandey, A.; Jaiswal, A.; Bhadauria, D.; Kaul, A.; Sharma, R. K.; Mohindra, S.; Pandey, G.; Goel, A.; Gupta, A.2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus InfectionReau, N.; Kwo, P. Y.; Rhee, S.; Brown, R. S., Jr.; Agarwal, K.; Angus, P.; Gane, E.; Kao, J. H.; Mantry, P. S.; Mutimer, D.; Reddy, K. R.; Tran, T. T.; Hu, Y. B.; Gulati, A.; Krishnan, P.; Dumas, E. O.; Porcalla, A.; Shulman, N. S.; Liu, W.; Samanta, S.; Trinh, R.; Forns, X.2018
MAGELLAN-2: Safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infectionReau, N.; Kwo, P. Y.; Rhee, S.; Brown, R. S.; Agarwal, K.; Angus, P.; Gane, E.; Kao, J. H.; Mantry, P. S.; Reddy, K. R.; Tran, T. T.; Hu, Y. B.; Gulati, A.; Ng, T. I.; Dumas, E. O.; Shulman, N.; Trinh, R.; Forns, X.2017
Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C VirusAssociated Cryoglobulinemia VasculitisCacoub, P.; Si Ahmed, S. N.; Ferfar, Y.; Pol, S.; Thabut, D.; Hezode, C.; Alric, L.; Comarmond, C.; Ragab, G.; Quartuccio, L.; Hegazy, M.; Poynard, T.; Resche Rigon, M.; Saadoun, D.2019
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis CDesnoyer, A.; Pospai, D.; Le, M. P.; Gervais, A.; Heurgue-Berlot, A.; Laradi, A.; Harent, S.; Pinto, A.; Salmon, D.; Hillaire, S.; et al.2016
Immunosuppressive and antiviral treatment of hepatitis c virusassociated glomerular disease: A long-term follow-upFabrizi, F.; Aghemo, A.; Lampertico, P.; Fraquelli, M.; Cresseri, D.; Moroni, G.; Passerini, P.; Donato, F. M.; Messa, P.2018
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver DiseaseGane, E.; Poordad, F.; Zadeikis, N.; Valdes, J.; Lin, C. W.; Liu, W.; Asatryan, A.; Wang, S.; Stedman, C.; Greenbloom, S.; et al.2019
SofosbuvirVelpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney TransplantationGaur, N.; Malhotra, V.; Agrawal, D.; Singh, S. K.; Beniwal, P.; Sharma, S.; Jhorawat, R.; Rathore, V.; Joshi, H.2019
Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: preliminary Results From a Multicenter StudyGentil, M. A.; Gonzalez-Corvillo, C.; Perello, M.; Zarraga, S.; Jimenez-Martin, C.; Lauzurica, L. R.; Alonso, A.; Franco, A.; Hernandez-Marrero, D.; Sanchez-Fructuoso, A.2016
Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patientsGevers, T. J.; Burger, D.; Schipper-Reintjes, E.; Kooistra, M. P.; Richter, C.2016
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysisGragnani, L.; Cerretelli, G.; Lorini, S.; Steidl, C.; Giovannelli, A.; Monti, M.; Petraccia, L.; Sadalla, S.; Urraro, T.; Caini, P.; et al.2018
Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With Renal DysfunctionIshigami, M.; Hayashi, K.; Honda, T.; Kuzuya, T.; Ishizu, Y.; Ishikawa, T.; Nakano, I.; Urano, F.; Kumada, T.; Yoshioka, K.; et al.2017
Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot studyKawakami, Y.; Imamura, M.; Ikeda, H.; Suzuki, M.; Arataki, K.; Moriishi, M.; Mori, N.; Kokoroishi, K.; Katamura, Y.; Ezaki, T.; et al.2016
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infectionLawitz, E.; Flisiak, R.; Abunimeh, M.; Sise, M. E.; Park, J. Y.; Kaskas, M.; Bruchfeld, A.; Worns, M. A.; Aglitti, A.; Zamor, P. J.; et al.2020
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label studyLawitz, E.; Landis, C. S.; Flamm, S. L.; Bonacini, M.; Ortiz-Lasanta, G.; Huang, J.; Zhang, J.; Kirby, B. J.; De-Oertel, S.; Hyland, R. H.; et al.2020
Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: a Post-Hoc Analysis of Phase 3 Clinical TrialsMehta, D. A.; Cohen, E.; Charafeddine, M.; Cohen, D. E.; Bao, Y.; Sanchez Gonzalez, Y.; Tran, T. T.2017
Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysisMehta, R.; Desai, K.; Kabrawala, M.; Nandwani, S.; Shah, J.; Desai, N.; Parekh, V.2018
A randomized open-label trial of paritaprevir plus ritonavir plus ombitasvir in the treatment of HCV genotype 4-infected patients with stage 4-5 chronic kidney diseaseSanai, F.; Babatin, M.; Khan, M. Q.; Alghamdi, H. S.; Alswat, K. A.; Aleid, H.; Alqahtani, A.; Albiladi, H.; Alghamdi, A. S.; Batwa, F. A.; Aljumah, A. A.; Alalwan, A. M.; Aldarsouny, T.; Basubiah, J.; Abdo, A.; Alashgar, H.2018
Erratum to: Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysisToyoda, H.; Kumada, T.; Tada, T.; Takaguchi, K.; Ishikawa, T.; Tsuji, K.; Zeniya, M.; Iio, E.; Tanaka, Y.2016
A pragmatic approach to optimizing the efficacy of elbasvir/grazoprevir using baseline viral load in participants with hepatitis C virus (HCV) genotype (GT)1a infection: a post hoc analysis of 11 clinical trialsJacobson, I; Rockstoh, J; Serfaty, L2017
Potential effect of hepatitis C treatment on renal, cardiovascular and metabolic extrahepatic manifestations: results from clinical trials of ombitasvir/paritaprevir/ritonavir and dasabuvir +/- ribavirinTran, T.T.2017
Successful Treatment of Chronic Hepatitis C Virus Infection with Sofosbuvir and Ledipasvir in Renal Transplant Recipients: ErratumEisenberger, U.2018
Long-term follow-up of cryoglobulinemic syndrome with renal involvement after daaAffatato, S.; Pollastri, E.; Belotti, E.; Zani, R.; Zaltron, S.; Spinetti, A.; Castelli, F.; Scolari, F.2020
Detection of Hepatitis C Antibodies Without Viral Transmission in Hepatitis C-Negative Recipients Receiving Kidneys From Hepatitis C-Positive Donors Treated With Direct-Acting Antiviral TherapyAgarwal, N.; Davis, R. J.; Gracey, D. M.; Wong, G.; Kable, K.; Wong, J. K. W.; Nankivell, B. J.; Strasser, S.; Wyburn, K.2018
Superiority of peginterferon -2a and ribavirin combination over peginterferon -2a monotherapy in the management of hemodialysis patients with chronic Hepatitis C virus infectionAl-Ghamdi, S. M. G.; Alaulaqi, N.; Al-Amoudi, A. A.; Alghamdi, A.; Zagnoon, A.; Sadiq, B. B.2017
Pretreatment circulating cryoglobulin predicts improvement in patient reported fatigue during directing acting antiviral therapy for chronic hepatitis c infectionAl-Jashaami, L.; Abidali, H.; Patel, A.; Choi, M.; Pedersen, M.; Seetharam, A. B.2017
Persistent hepatitis C virusassociated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapyArtemova, M.; Abdurakhmanov, D.; Ignatova, T.; Mukhin, N.2017
Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy and treatment in CHC in hemodialysis population. Target C trial-A placebo randomized control clinical trialBasu, P.; Siriki, R.; Shah, N. J.; Farhat, S.; Mittimani, K.; Atluri, S.2013
Adherence to pangenotypic glecaprevir/pibrentasvir treatment and SVR12 in HCVinfected patients: an integrated analysis of the phase 2/3 clinical trial programBrown, A2017
Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia VasculitisCacoub, P.; Si Ahmed, S. N.; Ferfar, Y.; Pol, S.; Thabut, D.; Hezode, C.; Alric, L.; Comarmond, C.; Ragab, G.; Quartuccio, L.; Hegazy, M.; Poynard, T.; Resche Rigon, M.; Saadoun, D.2019
All oral interferon-free antivirals for hepatitis c virus cryoglobulinemia vasculitis: A long term follow up multicenter international studyCacoub, P.; Si Ahmed, S. N.; FerFar, Y.; Pol, S. N.; Thabut, D.; Hezode, C.; Albric, L.; Comarmond, C.; Ragab, G.; Quartuccio, L.; Hegazy, M.; Poynard, T.; Resche-Rigon, M.; Saadoun, D.2017
Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals eraCacoub, P.; Vautier, M.; Desbois, A. C.; Lafuma, A.; Saadoun, D.2017
Interferon-free antivirals for hepatitis c virus-associated cryoglobulinemia vasculitis: A long-term follow-up studyCacoub, P.; Si ahmed, S. N.; Ferfar, Y.; Pol, S.; Thabut, D.; Hezode, C.; Alric, L.; Comarmond, C.; Ragab, G.; Quatuccio, L.; Hegazy, M.; Poynard, T.; Resche Rigon, M.; Saadoun, D.2018
Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?Cannon, R. M.; Locke, J. E.; Orandi, B. J.; Anderson, D. J.; Davis, E. G.; Mackelaite, L.; Dave, H.; Eng, M.; Jones, C. M.2020
Interactions between immunosuppressive therapy and direct-acting antivirals in kidney transplant recipient with hepatitis C infectionCarta, P.; Curci, F.; Caroti, L.; Aida, L.; Di Maria, L.; Cirami, L.2020
The Efficacy and Safety of Sofosbuvir/Ledipasvir Therapy in Patients on Long-term Hemodialysis with Hepatitis C Virus InfectionCavoli, G. L.; Schillaci, O.; Zagarrigo, C.; Servillo, F.; Li Cavoli, T. V.; Palmeri, M.; Rotolo, U.2018
Cryoglobulin mediated kidney disease: HCV infection, histological patterns, role of rituximab. monocentric reportCerami, C.; Scichilone, L. M.; Mascia, M. T.; Campioli, D.; Cappelli, G.2018
Sofosbuvir/Ribavirin treatment in patients with genotype 2, Hepatitis C Virus infection and symptomatic mixed cryoglobulinemia: An interim analysis on safety, efficacy and impact on quality of lifeCerretelli, G.; Gragnani, L.; Monti, M.; Arena, U.; Fognani, E.; Petraccia, L.; Gianni, E.; Sollima, S.; Brancaccio, G.; Galli, M.; Gaeta, G. B.; Zignego, A. L.2017
Interactive Impacts from Hepatitis C Virus Infection and Mixed Cryoglobulinemia on Complement LevelsChang, M. L.; Hu, J. H.; Chen, W. T.; Lin, M. S.; Kuo, C. J.; Chen, S. C.; Chien, R. N.2020
Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant: A multicenter studyChascsa, D. M.; Mousa, O. Y.; Pungpapong, S.; Zhang, N.; Chervenak, A.; Nidamanuri, S.; Rodriguez, E.; Franco, D.; Ryland, K.; Keaveny, A. P.; Huskey, J. L.; Smith, M.; Reddy, K. S.; Taner, C. B.; Vargas, H. E.; Aqel, B. A.2018
Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevirChayama, K.; Hayes, C. N.2017
Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trialCheema, S. U. R.; Rehman, M. S.; Hussain, G.; Cheema, S. S.; Gilani, N.2019
Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirinChen, C. C.; Tung, S. Y.; Wei, K. L.; Shen, C. H.; Chang, T. S.; Chen, W. M.; Xu, H. W.; Yen, C. W.; Chen, Y. H.; Lu, S. N.; Hung, C. H.2020
Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant studyChen, K.; Lu, P.; Song, R.; Zhang, J.; Tao, R.; Wang, Z.; Zhang, W.; Gu, M.2017
High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapyChen, W. M.; Wei, K. L.; Tung, S. Y.; Shen, C. H.; Chang, T. S.; Yen, C. W.; Hsieh, Y. Y.; Chiu, W. N.; Hu, J. H.; Lu, S. N.; Hung, C. H.2020
Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivalsChen, Y. C.; Li, C. Y.; Tsai, S. J.; Chen, Y. C.2019
Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in TaiwanCheng, P. N.; Chen, C. Y.; Yu, M. L.; Lin, C. C.; Lin, C. Y.; Peng, C. Y.; Tseng, K. C.; Lo, C. C.; Tseng, I. H.; Liu, C. J.2020
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatmentCheng, T. S.; Liang, P. C.; Huang, C. F.; Yeh, M. L.; Huang, C. I.; Lin, Z. Y.; Chen, S. C.; Huang, J. F.; Dai, C. Y.; Hsieh, P. H.; Chuang, W. L.; Yu, M. L.2020
Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinaemia: an 8-year prospective studyCheng, Y. T.; Cheng, J. S.; Lin, C. H.; Chen, T. H.; Lee, K. C.; Chang, M. L.2020
Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter ExperienceChevallier, E.; Bchler, M.; Caillard, S.; Bouvier, N.; Colosio, C.; Rivalan, J.; Sayegh, J.; Bertrand, D.; Le Meur, Y.; Thierry, A.; Garrouste, C.; Rerolle, J. P.; Rostaing, L.; Gatault, P.2020
Successful treatment of HCV-related glomerulonephritis with sofosbuvir and daclatasvirChia, X. X.; Cherepanoff, S.; Danta, M.; Furlong, T.2018
Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans populationChoi, D. T.; Puenpatom, A.; Yu, X.; Erickson, K. F.; Kanwal, F.; El-Serag, H. B.; Kramer, J. R.2020
Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysisChoudhary, N. S.; Kumar, A.; Bodh, V.; Bansal, S. B.; Sharma, R.; Jain, M.; Saigal, S.; Saraf, N.2017
Clinico-immunologic outcomes of HCV-cured cryoglobulinemia: lower relapse rate with interferon-based than interferon-free therapyColantuono, S.; Marrapodi, R.; Del Padre, M.; Collalti, G.; Garzi, G.; De Santis, A.; Fiorilli, M.; Basili, S.; Visentini, M.; Casato, M.2020
Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitisColantuono, S.; Mitrevski, M.; Yang, B.; Tola, J.; Carlesimo, M.; De Sanctis, G. M.; Fiorilli, M.; Casato, M.; Visentini, M.2017
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia VasculitisComarmond, C.; Garrido, M.; Pol, S.; Desbois, A. C.; Costopoulos, M.; Le Garff-Tavernier, M.; Si Ahmed, S. N.; Alric, L.; Fontaine, H.; Bellier, B.; Maciejewski, A.; Rosenzwajg, M.; Klatzmann, D.; Musset, L.; Poynard, T.; Cacoub, P.; Saadoun, D.2017
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C VirusInduced Cryoglobulinemia VasculitisComarmond, C.; Garrido, M.; Pol, S.; Desbois, A. C.; Costopoulos, M.; Le Garff-Tavernier, M.; Si Ahmed, S. N.; Alric, L.; Fontaine, H.; Bellier, B.; Maciejewski, A.; Rosenzwajg, M.; Klatzmann, D.; Musset, L.; Poynard, T.; Cacoub, P.; Saadoun, D.2017
Direct-acting antiviral-based therapy restores immune tolerance in hepatitis c-induced cryoglobulinemia vasculitisComarmond, C.; Garrido, M.; Desbois, A. C.; Costopoulos, M.; Le Garff-Tavernier, M.; Si Ahmed, S. N.; Alric, L.; Fontaine, H.; Bellier, B.; Maciejewski, A.; Rosenzwajg, M.; Klatzmann, D.; Musset, L.; Poynard, T.; Cacoub, P.; Saadoun, D.2017
Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunctionCox-North, P.; Hawkins, K. L.; Rossiter, S. T.; Hawley, M. N.; Bhattacharya, R.; Landis, C. S.2017
Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center studyCrismale, J. F.; Khalid, M.; Bhansali, A.; De Boccardo, G.; Khaim, R.; Florman, S. S.; Shapiro, R.; Schiano, T. D.2020
Treatment of HCV-induced cryoglobulinemic vasculitis with new direct acting antiviral (DAA) regimensCristin, D.; Wieland, A. C.; Langness, J.; Darling, J. M.; Lim, J. K.; Feld, J. J.; Nelson, D. R.; Fried, M. W.; Vainorius, M.; Morelli, G. J.; Kuo, A.; Everson, G. T.2017
Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipientsD'Ambrosio, R.; Vinci, M.; Franchina, M.; Parlati, L.; Zaltron, S.; Pasulo, L.; Campise, M.; Messa, P.; Pol, S.; Lampertico, P.2019
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life studyD'Ambrosio, R.; Pasulo, L.; Giorgini, A.; Spinetti, A.; Messina, E.; Fanetti, I.; Puoti, M.; Aghemo, A.; Vigan, P.; Vinci, M.; Menzaghi, B.; Lombardi, A.; Pan, A.; Pigozzi, M. G.; Grossi, P.; Lazzaroni, S.; Spinelli, O.; Invernizzi, P.; Maggiolo, F.; Terreni, N.; Monforte, A. D.; Poggio, P. D.; Taddei, M. T.; Colombo, S.; Pozzoni, P.; Molteni, C.; Brocchieri, A.; Bhoori, S.; Buscarini, E.; Centenaro, R.; Mendeni, M.; Colombo, A. E.; Di Marco, M.; Dionigi, E.; Bella, D.; Borghi, M.; Zuin, M.; Zaltron, S.; Noventa, F.; Annalisa, S.; Lampertico, P.; Fagiuoli, S.2020
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis CD'Ambrosio, R.; Pasulo, L.; Puoti, M.; Vinci, M.; Schiavini, M.; Lazzaroni, S.; Soria, A.; Gatti, F.; Menzaghi, B.; Aghemo, A.; Capelli, F.; Rumi, M. G.; Morini, L.; Giorgini, A.; Pigozzi, M. G.; Rossini, A.; Maggiolo, F.; Pan, A.; Memoli, M.; Spinelli, O.; Del Poggio, P.; Saladino, V.; Spinetti, A.; De Bona, A.; Capretti, A.; Uberti-Foppa, C.; Bonfanti, P.; Terreni, N.; Menozzi, F.; Colombo, A. E.; Giglio, O.; Centenaro, R.; Borghi, M.; Baiguera, C.; Picciotto, V.; Landonio, S.; Gori, A.; Magnani, C.; Noventa, F.; Paolucci, S.; Lampertico, P.; Fagiuoli, S.2019
DAA Therapy in Hepatitis C in Patients With Chronic Kidney Disease: New Information for GFR Category G4 and G5Dai, C. Y.; Huang, J. F.; Chuang, W. L.; Yu, M. L.2020
Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled studyDammacco, F.; Sansonno, D.; Han, J. H.; Shyamala, V.; Cornacchiulo, V.; Iacobelli, A. R.; Lauletta, G.; Rizzi, R.1994
Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term studyDammacco, F.; Tucci, F. A.; Lauletta, G.; Gatti, P.; De Re, V.; Conteduca, V.; Sansonno, S.; Russi, S.; Mariggi, M. A.; Chironna, M.; et al.2010
Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatmentDaniel, K. E.; Saeian, K.; Rizvi, S.2020
Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infectionDaniş, N.; Toz, H.; Unal, N.; Yilmaz, M.; Turan, I; Gunsar, F.; Karasu, Z.; Ersoz, G.; Ozkahya, M.; Akarca, U. S.2019
Use of HCV Ab+/NAT- donors in HCV nave renal transplant recipients to expand the kidney donor poolDao, A.; Cuffy, M.; Kaiser, T. E.; Loethen, A.; Cafardi, J.; Luckett, K.; Rike, A. H.; Cardi, M.; Alloway, R. R.; Govil, A.; Diwan, T.; Sherman, K. E.; Shah, S. A.; Woodle, E. S.2019
Efficacy and safety of new direct-acting antivirals in kidney transplant recipients with chronic hepatitis C: a single-center studyDarema, M.; Cholongitas, E.; Filiopoulos, V.; Marinaki, S.; Pavlopoulou, I. D.; Tsoubou, I.; Boletis, J. N.; Papatheodoridis, G. V.2020
Immunosuppressive treatment does not improve kidney survival in patients with hcv cryoglobulinaemia treated with direct-acting antiviralsPérez de José, A; Carbayo, J.; Pocurull, A.; Huerta, A.; Corona, C. M. C.; Bosch, T. B.; Shabaka, A.; Terrada, N. R.; Valenzuela, L. M.; Goicoechea, M.2020
A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (RTX) monotherapy versus the best available treatment in patients with mixed cryoglobulinemia syndromeDe Vita, S.; Quartuccio, L.; Isola, M.; Masolini, P.; Sacco, S.; De Marchi, G.; Mazzaro, C.2010
A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitisDe Vita, S.; Quartuccio, L.; Isola, M.; Mazzaro, C.; Scaini, P.; Lenzi, M.; Campanini, M.; Naclerio, C.; Tavoni, A.; Pietrogrande, M.; et al.2012
Combined NS5A & NS5B Nucleotide Inhibitor Therapy For Patients With Chronic Hepatitis C With Stage 5 Chronic Kidney Disease On HemodialysisDebnath, P.; Chandnani, S.; Rathi, P.; Nair, S.; Pawar, V.; Contractor, Q.2020
Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft FunctionEisenberger, U.; Friebus-Kardash, J.; Guberina, H.; Kribben, A.; Witzke, O.; Willuweit, K.; Gerken, G.; Herzer, K.2019
Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized StudyDurand, C. M.; Barnaba, B.; Yu, S.; Brown, D. M.; Chattergoon, M. A.; Bair, N.; Naqvi, F. F.; Sulkowski, M.; Segev, D. L.; Desai, N. M.2020
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized TrialDurand, C. M.; Bowring, M. G.; Brown, D. M.; Chattergoon, M. A.; Massaccesi, G.; Bair, N.; Wesson, R.; Reyad, A.; Naqvi, F. F.; Ostrander, D.; Sugarman, J.; Segev, D. L.; Sulkowski, M.; Desai, N. M.2018
Short course pre & post exposure DAA prophylaxis in hepatitis C negative recipients of hepatitis C nucleic acid positive kidney transplantsDurand, C.; Barnaba, B.; Brown, D.; Bair, N.; Naqvi, F.; Bowring, M. G.; Ostrander, D.; Segev, D.; Sulkowski, M. S.; Massaccesi, G.; Rousseau, K.; Chattergoon, M. A.; Desai, N. M.2019
Impact of direct antiviral agents on health-related quality of life in patients of chronic hepatitis C with chronic kidney diseaseDuseja, A.; Tiwari, P.; Ramachandran, R.2018
Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C RegistryDultz, G.; Mller, T.; Petersen, J.; Mauss, S.; Zimmermann, T.; Muche, M.; Simon, K. G.; Berg, T.; Zeuzem, S.; Hppe, D.; Bker, K.; Wedemeyer, H.; Welzel, T. M.2018
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipientsDuerr, M.; Schrezenmeier, E. V.; Lehner, L. J.; Bergfeld, L.; Glander, P.; Marticorena Garcia, S. R.; Althoff, C. E.; Sack, I.; Brakemeier, S.; Eckardt, K. U.; Budde, K.; Halleck, F.2019
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label studyLawitz, E.; Landis, C. S.; Flamm, S. L.; Bonacini, M.; Ortiz-Lasanta, G.; Huang, J.; Zhang, J.; Kirby, B. J.; De-Oertel, S.; Hyland, R. H.; Osinusi, A. O.; Brainard, D. M.; Robson, R.; Maliakkal, B. J.; Gordon, S. C.; Gane, E. J.2020
A Phase 2b, Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 HCV-Infected Subjects With Renal InsufficiencyDrks2020 (2014 protocol)
Benefit of direct-acting antiviral therapy in hepatitis C virus (HCV) monoinfected and HIV-HCV coinfected patients with mixed cryoglobulinemiaDiakite, M.; Hartig-Lavie, K.; Miailhes, P.; Pradat, P.; Uhres, A. C.; Zoulim, F.; Sarda, M. N.2017
Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals EraDevresse, A.; Delire, B.; Lazarus, J. V.; Kabamba, B.; De Meyer, M.; Mourad, M.; Buemi, A.; Darius, T.; Cambier, J. F.; Goffin, E.; Jadoul, M.; Kanaan, N.2020
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis CDesnoyer, A.; Pospai, D.; L, M. P.; Gervais, A.; Heurgu-Berlot, A.; Laradi, A.; Harent, S.; Pinto, A.; Salmon, D.; Hillaire, S.; Fontaine, H.; Zucman, D.; Simonpoli, A. M.; Muret, P.; Larrouy, L.; Bernard Chabert, B.; Descamps, D.; Yazdanpanah, Y.; Peytavin, G.2016
Evaluation of HCV clearance by hemodialysisEuctr, A. T.2009
A randomized, open label, multicenter, parallel group study evaluating the efficacy and safety of 135 mcg and 90 mcg of Pegasys given as monotherapy to patients with chronic hepatitis C and end-stage renal disease undergoing hemodialysisEuctr, I. T.2007
HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)Nct2016
Treatment of Chronic Hepatitis C Infection Among Egyptian Kidney Transplant Recipients: A Pilot StudyEl Maghrabi, H. M.; Elmowafy, A. Y.; Donia, A. F.; Ismail, M. I.; El-Hendy, Y. A.; Soliman, R.; Shiha, G. E.; Bakr, M. A.2019
The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infectionEl-Serag, H. B.; Christie, I. C.; Puenpatom, A.; Castillo, D.; Kanwal, F.; Kramer, J. R.2019
Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairmentEletreby, R.; El-Serafy, M.; Anees, M.; Kasem, G.; Salama, M.; Elkhouly, R.; Hamdy, M.; Abdel Haleem, H.; Kamal, E.; Abdel-Razek, W.; Salama, R.; Elshenawy, M.; Shafeek, A.; Hassany, M.; El-Sayed, M. H.; El-Shazly, Y.; Esmat, G.2020
Effect of anemia on efficacy and safety of chronic hepatitis c treatment among renal patients using direct acting anti-virusElmowafy, A.; Abbas, M.; Elmaghrabi, H.; Soliman, R.; Elwasif, S.; Sheashaa, H.; Shiha, G.; Rostaing, L.; Bakr, M.2020
High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agentsElmowafy, A. Y.; El Maghrabi, H. M.; Mashaly, M. E.; Eldahshan, K. F.; Rostaing, L.; Bakr, M. A.2019
Ombitasvir, paritaprevir, and ritonavir for treatment of chronic hepatitis C hemodialysis dependent patientsElmowafy, A. Y.; Elmaghrabi, H. M.; Zahab, M. A.; Eldahshan, K. F.; Soliman, R.; Elbasiony, M.; Mashaly, M. E.; Matter, Y. E.; Elwasif, S. M.; Donia, A. F.; et al.2018
Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a realityElmowafy, A. Y.; El Maghrabi, H. M.; Eldahshan, K. F.; Refaie, A. F.; Elbasiony, M. A.; Matter, Y. E.; Saleh, H. H.; Shiha, G. E.; Rostaing, L.; Bakr, M. A.2019
The effect of anemia on the efficacy and safety of treating chronic hepatitis C infection with direct-acting antivirals in patients with chronic kidney diseaseElmowafy, A. Y.; Abbas, M. H.; Denewar, A. A.; Mashaly, M. E.; Shiha, G.; El Wasif, S. M.; Rostaing, L.; Bakr, M. A.2020
Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in EgyptElsharkawy, A.; Fouad, R.; El Akel, W.; El Raziky, M.; Hassany, M.; Shiha, G.; Said, M.; Motawea, I.; El Demerdash, T.; Seif, S.; Gaballah, A.; El Shazly, Y.; Makhlouf, M. A. M.; Waked, I.; Abdelaziz, A. O.; Yosry, A.; El Serafy, M.; Thursz, M.; Doss, W.; Esmat, G.2017
Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed CryoglobulinemiaEmery, J. S.; Kuczynski, M.; La, D.; Almarzooqi, S.; Kowgier, M.; Shah, H.; Wong, D.; Janssen, H. L. A.; Feld, J. J.2017
HCV-infected solid organ donors, direct-acting antivirals and the current challengesFabrizi, F.; Cerutti, R.; Silva, M.2020
Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-upFabrizi, F.; Aghemo, A.; Lampertico, P.; Fraquelli, M.; Cresseri, D.; Moroni, G.; Passerini, P.; Donato, F. M.; Messa, P.2018
[Serum CXCL-10 level in chronic hepatitis C patients with cryoglobulinemia and its influence on antiviral therapy]Fan, X. H.; Deng, Z. H.; Xu, X. Y.2016
Outcomes of patients with hcv-associated cryoglobulinemia after ifn-free therapy: a monocenter retrospective studyZuglian, G.; Odolini, S.; Carriero, C.; Chirico, C.; Marchese, V.; Nasta, P.; Zaltron, S.; Spinetti, A.; Castelli, F.2019
Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label studyFeld, J. J.; Cypel, M.; Kumar, D.; Dahari, H.; Pinto Ribeiro, R. V.; Marks, N.; Kamkar, N.; Bahinskaya, I.; Onofrio, F. Q.; Zahoor, M. A.; Cerrochi, O.; Tinckam, K.; Kim, S. J.; Schiff, J.; Reichman, T. W.; McDonald, M.; Alba, C.; Waddell, T. K.; Sapisochin, G.; Selzner, M.; Keshavjee, S.; Janssen, H. L. A.; Hansen, B. E.; Singer, L. G.; Humar, A.2020
The Real-Eorld Israeli experience of treating mild and severe chronic hepatitis C patients with elbasvir/grazoprevir: A large multi-center cohort studyZuckerman, E.; Ashkenazi, E.; Kovalev, Y.; Cohen-ezra, O.; Veitsman, E.; Saadi, T.; Carlebach, M.; Hazzan, R.; Safadi, R.; Goldberg, T.; Oren, R.; Ashur, Y.; Carmiel, M.; Kitay, Y.; Hadary, R.; Abu-Mouch, S.; Bruk, R.; Menachem, Y.; Katchman, H.; Shibolet, O.; Arbib, O. S.; Shirin, H.; Tur-Kaspa, R.; Braun, M.; Cohen-Naftaly, M.; Shlomai, A.2019
The real-world israeli experience of treating chronic hepatitis C (CHC), genotype 1 (GT1) and genotype 4 (GT4) patients with advanced fibrosis with elbasvir\ grazoprevir: A large multi-center cohortZuckerman, E.; Ashkenazi, E.; Kovalev, Y.; Cohen-Ezra, O.; Veitsman, E.; Saadi, T.; Carlebach, M.; Hazzan, R.; Safadi, R.; Goldberg-Clein, T.; Oren, R.; Ashur, Y.; Carmiel, M.; Kitay, Y.; Hadari, R.; Abu-Mouch, S. M.; Bruk, R.; Menachem, Y.; Kathcman, H.; Shibolet, O.; Sneh, O.; Shirin, H.; Tur-Kaspa, R.; Braun, M.; Cohen-Naftaly, M.; Shlomai, A.2017
Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid-term follow-up in a single-center cohort studyFernandez-Ruiz, M.; Polanco, N.; Garca-Santiago, A.; Muoz, R.; Hernndez, A. M.; Gonzlez, E.; Mercado, V. R.; Fernndez, I.; Aguado, J. M.; Praga, M.; Andrs, A.2018
Interferon alfa-2b in mixed cryoglobulinaemia: a controlled crossover trialFerri, C.; Marzo, E.; Longombardo, G.; La Civita, L.; Lombardini, F.; Giuggioli, D.; Vanacore, R.; Liberati, A. M.; Mazzoni, A.; Greco, F.1993
Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in ChinaZhang, J.; Sun, W.; Lin, J.; Tian, Y.; Ma, L.; Zhang, L.; Zhu, Y.; Qiu, W.2019
Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trialFerri, C.; Marzo, E.; Longombardo, G.; Lombardini, F.; La Civita, L.; Vanacore, R.; Liberati, A. M.; Gerli, R.; Greco, F.; Moretti, A.; et al.1993
Association of Hepatitis C and B Virus Infection with CKD and Impact of Hepatitis C Treatment on CKDZhang, H.; Xu, H.; Wu, R.; Yu, G.; Sun, H.; Lv, J.; Wang, X.; Chi, X.; Gao, X.; Kong, F.; Zhang, M.; Hang, L.; Jiang, J.; Pan, Y.; Niu, J.2019
Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4Zarbska-Michaluk, D.; Jaroszewicz, J.; Buczyska, I.; Simon, K.; Lorenc, B.; Tudrujek-Zdunek, M.; Tomasiewicz, K.; Sitko, M.; Garlicki, A.; Janczewska, E.; Dybowska, D.; Halota, W.; Pawowska, M.; Pabjan, P.; Mazur, W.; Czau-Andrzejuk, A.; Berak, H.; Horban, A.; Socha,; Klapaczyski, J.; Piekarska, A.; Blaszkowska, M.; Belica-Wdowik, T.; Dobracka, B.; Tronina, O.; Dero, Z.; Biakowska-Warzecha, J.; Laurans,; Flisiak, R.2020
Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO networkFlamm, S. L.; Bacon, B.; Curry, M. P.; Milligan, S.; Nwankwo, C. U.; Tsai, N.; Younossi, Z.; Afdhal, N.2018
Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trialsZamor, P. J.; Vierling, J.; Ghalib, R.; Luketic, V.; Ravendhran, N.; Balart, L.; Robertson, M.; Hwang, P.; Hanna, G. J.; Nguyen, B. Y.; Barr, E.; Talwani, R.; Pearlman, B.2018
Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain: a prospective studyFranco, A.; Moreso, F.; Merino, E.; Sancho, A.; Kanter, J.; Gimeno, A.; Balibrea, N.; Rodriguez, M.; Perez Contreras, F.2019
Pattern of HCV antibodies with special reference to NS5A reactivity in HCV-infected patients: relation to viral genotype, cryoglobulinemia and response to interferonFrangeul, L.; Cresta, P.; Perrin, M.; Duverlie, G.; Khorsi, H.; Musset, L.; Opolon, P.; Huraux, J. M.; Lunel, F.1998
Effectiveness of ombitasvir/paritaprevir/ritonavir-dasabuvir-ribavirin in hemodialysis patients with chronic HCVYildiz, O.; Aygen, B.; Gokahmetoglu, S.; Baltaci, S.; Mumcu, N.; Eren, E.2018
Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world settingYen, H. H.; Su, P. Y.; Zeng, Y. H.; Liu, I. L.; Huang, S. P.; Hsu, Y. C.; Chen, Y. Y.; Yang, C. W.; Wu, S. S.; Chou, K. C.2020
The incidence of cytomegalovirus infection after deceased-donor kidney transplantation from hepatitis-C antibody positive donors to hepatitis-C antibody negative recipientsYazawa, M.; Flp, T.; Cseprekal, O.; Talwar, M.; Balaraman, V.; Bhalla, A.; Azhar, A.; Kovesdy, C. P.; Eason, J. D.; Molnar, M. Z.2020
Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in TurkeyYaraş, S.; Üçbilek, E.; Özdoğan, O.; Ateş, F.; Altıntaş, E.; Sezgin, O.2019
Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairmentYap, D. Y. H.; Liu, K. S. H.; Hsu, Y. C.; Wong, G. L. H.; Tsai, M. C.; Chen, C. H.; Hsu, C. S.; Hui, Y. T.; Li, M. K. K.; Liu, C. H.; Kan, Y. M.; Yu, M. L.; Yuen, M. F.2020
Efficacy and safety of direct-acting antiviral-based treatment in hepatitis C virus infected patients with chronic renal function impairment: An updated systemic review and meta-analysisYang, H.; Hu, X.; Pu, L.; Ren, S.; Feng, Y.2020
Recurrent hyperkalemia in patients with chronic kidney disease and hepatitis C treated with direct antiviral agentsYan, T.; Wang, J.; Li, J.; Fu, S.; Chen, Y.; Hu, C.; Zhang, R.; Tian, Z.; Zhao, F.; Dong, J.; Liu, J.; Yang, Y.; Chen, T.; Zhao, Y.; He, Y.2019
Efficacy and Safety of Glecaprevir/Pibrentasvir for Chronic Hepatitis C Patients: A Systematic Review and Meta-analysisXu, H. Q.; Wang, C. G.; Xiao, P.; Gao, Y. H.2020
Highly effective treatment response and well tolerability by all oral direct acting antivirals for chronic hepatitis C patients post organ transplantationWu, S. H.; Loong, C. C.; Chu, C. J.; Su, C. W.; Lin, C. C.; Hsia, C. Y.; Liu, C.; Lee, S. D.; Wang, Y. J.; Lee, F. Y.; Linb, N. C.; Chen, C. Y.; Huang, Y. H.; Hou, M. C.2020
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register)Wiegand, J.; Buggisch, P.; Mauss, S.; Boeker, K. H. W.; Klinker, H.; Mller, T.; Gnther, R.; Serfert, Y.; Manns, M. P.; Zeuzem, S.; Berg, T.; Hinrichsen, H.; GH, C. Registry2019
HBV reactivation during direct-acting antiviral therapy in hepatitis B and C coinfected patients undergoing haemodialysisWang, J.; Hu, C.; Chen, Y.; Liu, Z.; Yu, Q.; Yang, S.; Dong, J.; Yang, Y.; Wu, Y.; Ren, D.; Yao, N.; Guo, D.; Tian, Z.; Zhao, Y.; Chen, T.; He, Y.; Liu, J.2019
Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: A systematic review and meta-analysisWang, X.; Fan, X.; Deng, H.; Zhang, X.; Zhang, K.; Li, N.; Han, Q.; Lv, Y.; Liu, Z.2019
Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in PortugalWeigert, A.; Querido, S.; Carvalho, L.; Lebre, L.; Chagas, C.; Matias, P.; Birne, R.; Nascimento, C.; Jorge, C.; Adrago, T.; Bruges, M.; Machado, D.2018
Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C RegistryWelzel, T. M.; Hinrichsen, H.; Sarrazin, C.; Buggisch, P.; Baumgarten, A.; Christensen, S.; Berg, T.; Mauss, S.; Teuber, G.; Stein, K.; Deterding, K.; van Bmmel, F.; Heyne, R.; John, C.; Zimmermann, T.; Lutz, T.; Schott, E.; Hettinger, J.; Kleine, H.; Knig, B.; Hppe, D.; Wedemeyer, H.2017
Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysisFujii, H.; Kimura, H.; Kurosaki, M.; Hasebe, C.; Akahane, T.; Yagisawa, H.; Kato, K.; Yoshida, H.; Itakura, J.; Sakita, S.; Satou, T.; Okada, K.; Kusakabe, A.; Kojima, Y.; Kondo, M.; Morita, A.; Nasu, A.; Tamada, T.; Okushin, H.; Kobashi, H.; Tsuji, K.; Joko, K.; Ogawa, C.; Uchida, Y.; Mitsuda, A.; Sohda, T.; Ide, Y.; Izumi, N.2018
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver DiseaseGane, E.; Poordad, F.; Zadeikis, N.; Valdes, J.; Lin, C. W.; Liu, W.; Asatryan, A.; Wang, S.; Stedman, C.; Greenbloom, S.; Nguyen, T.; Elkhashab, M.; Wrns, M. A.; Tran, A.; Mulkay, J. P.; Setze, C.; Yu, Y.; Pilot-Matias, T.; Porcalla, A.; Mensa, F. J.2019
RUBY-II: efficacy and safety of a ribavirin-free ombitasvir/ paritaprevir/ritonavir +/- dasabuvir regimen in patients with severe renal impairment or end-stage renal disease and HCV Genotypes 1a or 4 infectionGane, E. J.; Sola, R.; Cohen, E.; Roberts, S. K.; George, J.; Skoien, R.; Riordan, S.; Mobashery, N.; Abunimeh, M.; Cohen, D. E.; et al.2016
'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal diseaseGarca-Agudo, R.; Aoufi-Rabih, S.; Salgueira-Lazo, M.; Gonzlez-Corvillo, C.; Fabrizi, F.2018
Sofosbuvir-Velpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney TransplantationGaur, N.; Malhotra, V.; Agrawal, D.; Singh, S. K.; Beniwal, P.; Sharma, S.; Jhorawat, R.; Rathore, V.; Joshi, H.2020
Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective studyGendia, M.; Lampertico, P.; Alfieri, C. M.; D'Ambrosio, R.; Gandolfo, M. T.; Campise, M. R.; Fabrizi, F.; Messa, P.2019
Sofosbuvir and Daclatasvir for treatment of Hepatitis-C in patients undergoing hemodialysisIrct20170614034526N2019
Anti-CD20 monoclonal antibody therapy for type II mixed cryoglobulinemia syndromeIsrctn2012
A multicenter phase II study assessed safety and efficacy of asunaprevir and daclatasvir in patients with chronic hepatitis C virus genotype 1 infection and end-stage renal disease requiring hemodialysisJprn, Umin2017 (2014 protocol)
Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infectionOtsuka, T.; Kawaguchi, Y.; Mizuta, T.; Ide, Y.; Koga, F.; Kumagai, T.; Yoshioka, W.; Murayama, K.; Rikitake, O.; Ikeda, Y.; Ozaki, I.2017
A prospective multicenter study for characterization of renal function G1b CHC patients with CKD-3 treated with elbasvir plus grazoprevirJprn, Umin2017
Antiviral therapy for HCV using direct acting antiviral drugs in patients with chronic hepatitis C undergoing hemodialysisJprn, Umin2015
Comprehensive analysis of iron and mineral-bone metabolism after HCV clearance by daclatasvir and asunaprevir combination therapy in genotype 1 HCV-infected hemodialysis patientsJprn, Umin2016
Comprehensive analysis of iron and mineral-bone metabolism after HCV clearance by glecaprevir and pibrentasvir therapy in HCV-infected hemodialysis patientsJprn, Umin2018
Efficacy and safety of daclatasvir and asunaprevir in chronic hepatitis C patients with hemodialysisJprn, Umin2017 (2015 protocol)
Efficacy and safety of glecaprevir and pibrentasvir in chronic hepatitis C patients with hemodialysisJprn, Umin2017
Efficacy and safety of Ledipasvir/Sofosbuvir in chronic hepatitis C of Genotype1b with chronic kidney disease(eGFR30-60ml/min/1.73m2)Jprn, Umin2017
Efficacy and safety of response-guided pegylated-interferon alpha-2a mono therapy in hemodialysis patients with chronic hepatitisCJprn, Umin2010
Efficacy and safety of simeprevir plus pegylated intereferon combination therapy for HCV genotype 1 patients with chronic renal failureJprn, Umin2013
Efficacy and safety of simeprevir with pegylated interferon alfa-2b and ribavirin in kidney transplant patients with chronic hepatitis CJprn, Umin2014
Predictive factors associated with virological response in Daclatasvir and Asunaprevir combination therapy for genotype1b-infected chronic hepatitis C patients : multicenter studyJprn, Umin2015
Safety and efficacy of Glecaprevir / Pibrentasvir combination therapy for chronic hepatitis C - including hemodialysis patientsJprn, Umin2018
The efficacy of paritaprevir and ombitasvir with a booster dose of ritonavir in genotype 1 HCV patients with hemodialysisJprn, Umin2016
Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal DiseaseNct2005
Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Nave Hemodialysis Patients With Chronic Hepatitis CNct2007
Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney DiseaseNct2001
Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic VasculitisNct2002
Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)Nct2014
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV InfectionNct2014
Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal diseaseVionnet, J.; Saouli, A. C.; Pascual, M.; Stucker, F.; Decosterd, L. A.; Moradpour, D.; Chtioui, H.2016
Fixed-dose combination of sofosbuvir and ledipasvir in the treatment of hepatitis C infection in patients on hemodialysis: Report of an initial experienceVikrant, S.; Jaryal, A.2018
RUBY-I: safety and efficacy of ombitasvir/paritaprevir/ ritonavir and dasabuvir with or without ribavirin in adults with genotype 1 chronic hepatitis C Virus (HCV) infection with severe renal impairment or end-stage renal diseaseVierling, J. M.; Lawitz, E.; Reddy, K. R.; Cohen, E.; Kemmer, N.; Morelli, G.; Zamor, P. J.; Bennett, M.; Bernstein, D. E.; Kowdley, K. V.; et al.2016
Therapy with direct acting antivirals in patients with hepatitis C virus related lymphoproliferative disorders and mixed cryogloglobulinemiaVenezia, L.; Troshina, G.; Tucci, A.; Ponzo, P.; Sacco, M.; Smedile, A.; Rizzetto, M.; Saracco, G. M.; Ciancio, A.2017
Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar)Vacchi, C.; Visentini, M.; Gragnani, L.; Fraticelli, P.; Tavoni, A.; Filippini, D.; Saccardo, F.; Lauletta, G.; Colantuono, S.; Atzeni, F.; Pioltelli, P.; Manfredi, A.; Casato, M.; Zignego, A. L.; Monti, G.; Pietrogrande, M.; Galli, M.; Sebastiani, M.2020
Safety of rituximab biosimilar for the treatment of cryoglobulinemic vasculitisVacchi, C.; Visentini, M.; Di Cicco, M.; Angelotti, F.; Lauletta, G.; Manfredi, A.; Filippini, D.; Tavoni, A.; Casato, M.; Castelnovo, L.; Monti, G.; Pietrogrande, M.; Salvarani, C.; Galli, M.; Sebastiani, M.2019
Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical TrialsTran, T. T.; Mehta, D.; Mensa, F.; Park, C.; Bao, Y.; Sanchez Gonzalez, Y.2018
Experience with antiviral agents for treatment of hepatitis C virus infection in hemodialysis patients on the kidney wait listTorun, D.; Soydas, B.; Tekkarismaz, N.; Ozelsancak, R.; Micozkadioglu, H.; Haberal, M.2019
Commercial insurance delays direct-acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipientsTorabi, J.; Rocca, J. P.; Ajaimy, M.; Melvin, J.; Campbell, A.; Akalin, E.; Liriano, L. E.; Azzi, Y.; Pynadath, C.; Greenstein, S. M.; Le, M.; Goldstein, D. Y.; Fox, A. S.; Carrero, J.; Weiss, J. M.; Powell, T.; Racine, A. D.; Reinus, J. F.; Kinkhabwala, M. M.; Graham, J. A.2020
Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic DonorsTerrault, N. A.; Burton, J.; Ghobrial, M.; Verna, E.; Bayer, J.; Klein, C.; Victor, D.; Mohan, S.; Trotter, J.; Dodge, J.; Niemann, C. U.; Rubin, R. A.2020
The effect of interferon-free direct-acting antivirals therapy on hepatitis C virus infected patients with CryoglobulinemiaTerashita, K.; Takagi, T.; Miyagishima, T.; Matsuda, S.; Suda, G.; Sakamoto, N.2019
Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infectionTavares, R. C. F.; Feldner, Acca; Pinho, J. R. R.; Uehara, S. N. O.; Emori, C. T.; Carvalho-Filho, R. J.; Silva, I. S. S.; Santana, R. A. F.; de Castro, V. F. D.; Castoli, G. T. F.; Cristovo, C. U.; Ferraz, Mlcg2017
Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experienceTatar, B.; Kse,; Ergun, N. C.; Turken, M.; Onlen, Y.; Ylmaz, Y.; Akhan, S.2019
Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal DiseaseTaneja, S.; Duseja, A.; De, A.; Mehta, M.; Ramachandran, R.; Kumar, V.; Kohli, H. S.; Gupta, K. L.; Dhiman, R. K.; Chawla, Y.2018
Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance hemodialysisTaneja, S.; Duseja, A.; Mehta, M.; De, A.; Verma, N.; Premkumar, M.; Dhiman, R. K.; Singh, V.; Singh, M. P.; Ratho, R. K.; Ramachandran, R.; Kumar, V.; Kohli, H. S.2020
Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis c virus-related cryoglobulinemic vasculitis, henoch-schnlein purpura, ankylosing spondylitis, and raynauds phenomenonTaha, R.; El-Haddad, H.; Almuallim, A.; Alshaiki, F.; Obaid, E.; Almoallim, H.2017
Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter StudyGentil, M. A.; Gonzlez-Corvillo, C.; Perell, M.; Zarraga, S.; Jimnez-Martn, C.; Lauzurica, L. R.; Alonso, A.; Franco, A.; Hernndez-Marrero, D.; Snchez-Fructuoso, A.2016
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocationGiannelli, F.; Moscarella, S.; Giannini, C.; Caini, P.; Monti, M.; Gragnani, L.; Romanelli, R. G.; Solazzo, V.; Laffi, G.; La Villa, G.; et al.2003
Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvirGoel, A.; Bhadauria, D. S.; Kaul, A.; Verma, A.; Tiwari, P.; Rungta, S.; Rai, P.; Gupta, A.; Aggarwal, R.2020
Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/minGoel, A.; Bhadauria, D. S.; Kaul, A.; Verma, P.; Mehrotra, M.; Gupta, A.; Sharma, R. K.; Rai, P.; Aggarwal, R.2019
Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysisGoel, A.; Bhadauria, D. S.; Kaul, A.; Prasad, N.; Gupta, A.; Sharma, R. K.; Rai, P.; Aggarwal, R.2017
Direct Acting Antivirals in Hepatitis C-Infected Kidney Transplant Recipients: Associations with Long-term Graft Failure and Patient MortalityGoetsch, M. R.; Tamhane, A.; Overton, E. T.; Towns, G. C.; Franco, R. A.2020
Sofosbuvir-Based HCV Treatment in Maintenance Hemodialysis Patients: A Single-Center StudyGohel, K.; Borasadia, P.2020
Direct-Acting Antivirals in Kidney Transplant Patients: Successful Hepatitis C Treatment and Short-Term Reduction in Urinary Protein/Creatinine RatiosGoetsch, M. R.; Tamhane, A.; Varshney, M.; Kapil, A.; Overton, E. T.; Towns, G. C.; Franco, R. A.2017
Effects of IFN-free treatment on the virological, clinical, immunological, and quality-of-life in patients with hcv-related mixed cryoglobulinemia: A prospective and controlled studyGragnani, L.; Cerretelli, G.; Monti, M.; Petraccia, L.; Sadalla, S.; Steidl, C.; Lorini, S.; Giovannelli, A.; Xheka, A.; Caini, P.; Simone, A.; Arena, U.; Zignego, A. L.2017
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysisGragnani, L.; Cerretelli, G.; Lorini, S.; Steidl, C.; Giovannelli, A.; Monti, M.; Petraccia, L.; Sadalla, S.; Urraro, T.; Caini, P.; Xheka, A.; Simone, A.; Arena, U.; Matucci-Cerinic, M.; Vergani, D.; Laffi, G.; Zignego, A. L.2018
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot studyGragnani, L.; Fabbrizzi, A.; Triboli, E.; Urraro, T.; Boldrini, B.; Fognani, E.; Piluso, A.; Caini, P.; Ranieri, J.; Monti, M.; et al.2014
Transplantation of viral-positive hepatitis C-positive kidneys into uninfected recipients offers an opportunity to increase organ accessGraham, J. A.; Torabi, J.; Ajaimy, M.; Akalin, E.; Liriano, L. E.; Azzi, Y.; Pynadath, C.; Greenstein, S. M.; Goldstein, D. Y.; Fox, A. S.; Weiss, J. M.; Powell, T. P.; Reinus, J. F.; Kinkhabwala, M. M.; Rocca, J. P.2020
Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infectionSuda, G.; Kurosaki, M.; Itakura, J.; Izumi, N.; Uchida, Y.; Mochida, S.; Hasebe, C.; Abe, M.; Haga, H.; Ueno, Y.; Masakane, I.; Abe, K.; Takahashi, A.; Ohira, H.; Furuya, K.; Baba, M.; Yamamoto, Y.; Kobayashi, T.; Kawakami, A.; Kumagai, K.; Terasita, K.; Ohara, M.; Kawagishi, N.; Umemura, M.; Nakai, M.; Sho, T.; Natsuizaka, M.; Morikawa, K.; Ogawa, K.; Sakamoto, N.2019
Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infectionSuda, G.; Hasebe, C.; Abe, M.; Kurosaki, M.; Itakura, J.; Izumi, N.; Uchida, Y.; Mochida, S.; Haga, H.; Ueno, Y.; Abe, K.; Takahashi, A.; Ohira, H.; Tsukuda, Y.; Furuya, K.; Baba, M.; Yamamoto, Y.; Kobayashi, T.; Inoue, J.; Terasita, K.; Ohara, M.; Kawagishi, N.; Izumi, T.; Nakai, M.; Sho, T.; Natsuizaka, M.; Morikawa, K.; Ogawa, K.; Sakamoto, N.2019
Safety and efficacy of paritaprevir/r and ombitasvir combination therapy for HCV infected patients with CryoglobulinemiaSuda, G.; Terashita, K.; Ogawa, K.; Morikawa, K.; Sakamoto, N.2018
A prospective, multicenter study of daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection on hemodialysisSung, J.; Uojima, H.; Ohtake, T.; Kinbara, T.; Oka, M.; Matsumoto, S.; Kobayashi, S.; Kako, M.2016
Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational studySurendra, M.; Raju, S. B.; Sridhar, N.; Vijay Kiran, B.; Rajesh, G.; Anvesh, G.; Raju, N.2018
Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in JapanSuzuki, F.; Hatanaka, N.; Bando, E.; Nakamura, K.; Komoto, A.2018
Use of Sofosbuvir-Based Treatment of Chronic Hepatitis C in Liver Transplant Recipients on HemodialysisSaab, S.; M, A. Jimenez; S, N. Bau; Choi, G.; Durazo, F. A.; M, M. El-Kabany; Han, S. B.; Busuttil, R. W.2017
Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia VasculitisSaadoun, D.; Pol, S.; Ferfar, Y.; Alric, L.; Hezode, C.; Si Ahmed, S. N.; de Saint Martin, L.; Comarmond, C.; Bouyer, A. S.; Musset, L.; Poynard, T.; Resche Rigon, M.; Cacoub, P.2017
PegIFNalpha/ribavirin/protease inhibitor combination in severe hepatitis C virus-Associated mixed cryoglobulinemia vasculitisSaadoun, D.; Resche Rigon, M.; Pol, S.; Thibault, V.; Blanc, F.; Pialoux, G.; Karras, A.; Bazin-Kara, D.; Cazorla, C.; Vittecoq, D.; et al.2015
Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of LifeSabbatini, M.; Capuano, I.; Camera, S.; Ferreri, L.; Buonanno, P.; Donnarumma, L.; Caporaso, N.; Morisco, F.2018
Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohortSaid, M.; Omar, H.; Soliman, Z.; Saad, Y.; Dabes, H.; Hamed, S.; ElSaeed, K.; ElShazly, Y.; ElSerafy, M.2019
Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing HemodialysisSalim, A.; Farooq, M. O.; Mengal, F. U. A.; Malik, K.2020
A randomized open-label trial of paritaprevir plus ritonavir plus ombitasvir in the treatment of HCV genotype 4-infected patients with stage 4-5 chronic kidney diseaseSanai, F.; Babatin, M.; Khan, M. Q.; Alghamdi, H. S.; Alswat, K. A.; Aleid, H.; Alqahtani, A.; Albiladi, H.; Alghamdi, A. S.; Batwa, F. A.; et al.2018
100% efficacy to ombitasvir/paritaprevir/ritonavir ( dasabuvir) with or without ribavirin in hepatitis C virus genotypes 1 and 4-infected hemodialysis patientsSanai, F. M.; Alghamdi, A. S.; Afghani, A.; Alswat, K. A.; Aseeri, A.; Babatin, M. A.2017
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney diseaseSanai, F. M.; Alghamdi, A. S.; Afghani, A. A.; Alswat, K.; AlZanbagi, A.; Alghamdi, M. N.; AlMousa, A.; Aseeri, M.; Assiri, A. M.; Babatin, M. A.2018
Off-label use of rituximab in patients with glomerulonephritis in a tertiary hospital: a retrospective observational studySans, C.; Bosch, J.; Agust, A.; Dans, I.; Agraz, I.2019
The Psychosocial Burden of HCV Infection and the Impact of Antiviral Therapy on the Quality of Life in Liver and Kidney Transplant Recipients: A Pilot StudySantonicola, A.; Bilancio, G.; Zingone, F.; Donnarumma, L.; Caputo, C.; Ciacci, C.2020
Efficacy of l-carnitine on the ribavirin induced hemolytic anemia for patients with HCV infectionSato, S.2018
Outcomes After Direct-Acting Antiviral Therapy Based on Donor Hepatitis C Serostatus Among Hepatitis C Virus-Infected Kidney Transplant RecipientsSedki, M.; Cortesi, C.; O'Brien, C.; Levy, C.; Martin, P.; Roth, D.; Bhamidimarri, K. R.2020
Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant RecipientsSharma, S.; Mukherjee, D.; Nair, R. K.; Datt, B.; Rao, A.2018
Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysisShehadeh, F.; Kalligeros, M.; Byrd, K.; Shemin, D.; Mylonakis, E.; Martin, P.; D'Agata, E. M. C.2020
Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal functionShin, H. P.; Park, J. A.; Burman, B.; Kozarek, R. A.; Siddique, A.2017
Sofosbuvir with NS5A inhibitors in hepatitis C virus (HCV) infected renal transplant recipientsSingh, A.; Kumari, S.; Leishangthem, B.; Singh, V.2018
Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiencySingh, A.; Kumari, S.; Kumar, P.; De, A.; Singh, V.2018
Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus InfectionSise, M. E.; Goldberg, D. S.; Kort, J. J.; Schaubel, D. E.; Alloway, R. R.; Durand, C. M.; Fontana, R. J.; Brown, R. S., Jr.; Friedewald, J. J.; Prenner, S.; Landis, J. R.; Fernando, M.; Phillips, C. C.; Woodle, E. S.; Rike-Shields, A.; Sherman, K. E.; Elias, N.; Williams, W. W.; Gustafson, J. L.; Desai, N. M.; Barnaba, B.; Norman, S. P.; Doshi, M.; Sultan, S. T.; Aull, M. J.; Levitsky, J.; Belshe, D. S.; Chung, R. T.; Reese, P. P.2020
Sirolimus conversion may suppress viral replication in hepatitis C virus-positive renal transplant candidatesSoliman, A.; Fathy, A.; Khashab, S.; Shaheen, N.; Soliman, M.2013
Direct-Acting Antivirals and Mixed Cryoglobulinemia Vasculitis: Long-Term Outcome of Patients Achieving HCV EradicationSollima, S.; Milazzo, L.; Antinori, S.; Galli, M.2017
Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapySollima, S.; Milazzo, L.; Peri, A. M.; Torre, A.; Antinori, S.; Galli, M.2016
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life CohortSperl, J.; Kreidlova, M.; Merta, D.; Chmelova, K.; Senkerikova, R.; Frankova, S.2018
Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV-related cryoglobulinemiaStefanutti, C.; Vivenzio, A.; Di Giacomo, S.; Labbadia, G.; Mazza, F.; D'Alessandri, G.; Ferraro, P. M.; Masala, C.2009
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R)Stein, K.; Stoehr, A.; Klinker, H.; Teuber, G.; Naumann, U.; John, C.; Heyne, R.; Serfert, Y.; Niederau, C.; Zeuzem, S.; Berg, T.; Wiegand, J.2020
Hepatitis C Virus in Kidney Transplant Recipients: A Problem on the Path to EradicationSuarez Benjumea, A.; Gonzalez-Corvillo, C.; Sousa, J. M.; Bernal Blanco, G.; Suer Poblet, M.; Perez Valdivia, M. A.; Gonzalez Roncero, F. M.; Acevedo, P.; Gentil Govantez, M. A.2016
The long-term impact of hepatitis C infection in kidney transplantation in the pre-direct acting antiviral eraRadhakrishnan, R. C.; Gopal, B.; Zachariah, U. G.; Abraham, P.; Mohapatra, A.; Valson, A. T.; Alexander, S.; Jacob, S.; Tulsidas, K. S.; David, V. G.; Varughese, S.2018
Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantationReddy, S.; Sharma, R. K.; Mehrotra, S.; Prasad, N.; Gupta, A.; Kaul, A.; Singh Bhadauria, D.2018
Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group TrialReese, P. P.; Abt, P. L.; Blumberg, E. A.; Van Deerlin, V. M.; Bloom, R. D.; Potluri, V. S.; Levine, M.; Porrett, P.; Sawinski, D.; Nazarian, S. M.; Naji, A.; Hasz, R.; Suplee, L.; Trofe-Clark, J.; Sicilia, A.; McCauley, M.; Gentile, C.; Smith, J.; Niknam, B. A.; Bleicher, M.; Reddy, K. R.; Goldberg, D. S.2018
Direct Acting Antivirals in patients with HCV-associated mixed cryoglobulinemia: Real life safety and efficacyRizzardini, G.; Schiavini, M.; Niero, F.; Magni, C.; Landonio, S.; Iemoli, E.; Bolis, M.; Colaneri, M.; Gubertini, G.2017
Sofosbuvir antiviral therapy in HCV patients with severe renal failureRodrguez Gil, F. J.; Prez Garrido, I.2017
Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimesRossato, G.; Tovo, C. V.; Almeida, P. R. L.2020
Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestationsRossi, C.; Jeong, D.; Wong, S.; McKee, G.; Butt, Z. A.; Buxton, J.; Wong, J.; Darvishian, M.; Bartlett, S.; Samji, H.; Yu, A.; Binka, M.; Alvarez, M.; Adu, P. A.; Tyndall, M.; Krajden, M.; Janjua, N. Z.2019
Rituximab monotherapy of severe HCV-related cryoglobulinemic vasculitis for more than 2 years: follow-up of a randomized controlled multicentre studyQuartuccio, L.; Zuliani, F.; Corazza, L.; Scaini, P.; Zani, R.; Lenzi, M.; Tavoni, A.; Sebastiani, M.; Baldovino, S.; Urraro, T.; et al.2014
Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral RegimensPuenpatom, A.; Hull, M.; McPheeters, J.; Schwebke, K.2017
Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b InfectionPuenpatom, A.; Cao, Y.; Yu, X.; Kanwal, F.; El-Serag, H. B.; Kramer, J. R.2020
Interventions for dialysis patients with hepatitis C virus (HCV) infectionPrabhu, R. A.; Nair, S.; Pai, G.; Reddy, N. P.; Suvarna, D.2015
Ledipasvir/sofosbuvir (LDV/SOF) for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 HCV infectionPol, S.; Aghemo, A.; Lin, L.; Hyland, R.; Yun, C.; Spellman, J.; Natha, M.; Brainard, D.; McHutchison, J.; Bourliere, M.; et al.2016
Direct-acting antivirals (DAAs) treatment improves hepatitis C virus (HCV)-associated mixed cryoglobulinemia symptomsPollastri, E.; Spinetti, A.; Odolini, S.; Tomasoni, L.; Lanza, P. A.; Bonito, A.; Zaltron, S.; Nasta, P.; Urbinati, L.; Biasi, L.; Festa, E.; Casari, S.; Affatato, S.; Belotti, E.; Zani, R.; Scaini, P.; Cancarini, G.; Castelli, F.2017
Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case ReportsPonziani, F. R.; Siciliano, M.; Lionetti, R.; Pasquazzi, C.; Gianserra, L.; D'Offizi, G.; Gasbarrini, A.; Pompili, M.2017
The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairmentPoustchi, H.; Majd Jabbari, S.; Merat, S.; Sharifi, A. H.; Shayesteh, A. A.; Shayesteh, E.; Minakari, M.; Fattahi, M. R.; Moini, M.; Roozbeh, F.; Mansour-Ghanaei, F.; Afshar, B.; Mokhtare, M.; Amiriani, T.; Sofian, M.; Somi, M. H.; Agah, S.; Maleki, I.; Latifnia, M.; Fattahi Abdizadeh, M.; Hormati, A.; Khoshnia, M.; Sohrabi, M.; Malekzadeh, Z.; Merat, D.; Malekzadeh, R.2020
Direct-acting antiviral agents for hepatitis C virus-mixed cryoglobulinaemia: dissociated virological and haematological responsesPozzato, G.; Mazzaro, C.; Artemova, M.; Abdurakhmanov, D.; Grassi, G.; Crosato, I.; Mauro, E.; Ghersetti, M.; Zorat, F.; Bomben, R.; Bulian, P.; Gattei, V.2020
Efficacy and safety of glecaprevir/pibrentasvir in renally-impaired patients with chronic hepatitis C virus genotype 1-6 infectionPersico, M.; Flisiak, R.; Abunimeh, M.; Sise, M.; Park, J. Y.; Kaskas, M.; Bruchfeld, A.; Wrns, M. A.; Aglitti, A.; Xue, Z.; Rullman, J.; Pocalla, A.; Lawitz, E.2018
Real-life effectivness and safety of glecaprevir/pibrentasvir in HCV infected patients with chronic kidney diseasePersico, M.; Aglitti, A.; Caruso, R.; Calvanese, G.; Di Siervi, P.; Grazia, N. M.; Tripodi, M. F.; Masarone, M.2019
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL studyPersico, M.; Aglitti, A.; Milella, M.; Coppola, C.; Messina, V.; Claar, E.; Gentile, I.; Sogari, F.; Pierri, P.; Surace, L. A.; Morisco, F.; Tundo, P.; Brancaccio, G.; Serviddio, G.; Gatti, P.; Termite, A. P.; Di Costanzo, G. G.; Caroleo, B.; Cozzolongo, R.; Coppola, N.; Longo, A.; Fontanella, L.; Federico, A.; Rosato, V.; Terrenato, I.; Masarone, M.2019
Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant RecipientsEtik, Ö.D.; Suna, N.; Öcal, S.; Selçuk, H.; Dağlı, Ü; Çolak, T.; Hilmioğlu, F.; Boyacoğlu, A. S.; Haberal, M.2019
Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single InstitutionPark, Y. J.; Woo, H. Y.; Heo, J.; Park, S. G.; Hong, Y. M.; Yoon, K. T.; Kim, D. U.; Kim, G. H.; Kim, H. H.; Song, G. A.; Cho, M.2020
Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experiencePasserini, M.; Schiavini, M.; Magni, C. F.; Landonio, S.; Niero, F.; Passerini, S.; Croci, A. L.; Bolis, M.; Scalzi, V.; Gubertini, G.; Ricci, E. D.; Galli, M.; Rizzardini, G.2018
Impact of grazoprevir and elbasvir in the treatment of hepatitis C virus-infected patients with chronic kidney disease and end-stage renal diseasePedraza, F.; Ladino, M.; Roth, D.2016
Interferon-alpha in mixed cryoglobulinaemia patients: a randomized, crossover-controlled trialPenny, R.1993
Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trialsNangia, G.; Vierling, J. M.; Kwo, P.; Brown, D. D.; Klopfer, S. O.; Robertson, M. N.; Haber, B. A.; Reddy, K. R.2020
Systematic review with meta-analysis: Real-world effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in AsiaNguyen, M.; Wei, B.; Yeo, Y. H.; Ogawa, E.; Stave, C.; Dang, S.; Li, Z.; Furusyo, N.; Zou, B.; Cheung, R.2018
Safety, Tolerability, and Efficacy of Sofosbuvir Plus Ribavirin in Elderly Patients Infected with Hepatitis C Virus Genotype 2Nishida, N.; Kono, M.; Minami, T.; Chishina, H.; Arizumi, T.; Takita, M.; Yada, N.; Ida, H.; Hagiwara, S.; Minami, Y.; Ueshima, K.; Sakurai, T.; Kudo, M.2016
The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter studyNozaki, A.; Atsukawa, M.; Kondo, C.; Toyoda, H.; Chuma, M.; Nakamuta, M.; Uojima, H.; Takaguchi, K.; Ikeda, H.; Watanabe, T.; Ogawa, S.; Itokawa, N.; Arai, T.; Hiraoka, A.; Asano, T.; Fujioka, S.; Ikegami, T.; Shima, T.; Ogawa, C.; Akahane, T.; Shimada, N.; Fukunishi, S.; Abe, H.; Tsubota, A.; Genda, T.; Okubo, H.; Mikami, S.; Morishita, A.; Moriya, A.; Tani, J.; Tachi, Y.; Hotta, N.; Ishikawa, T.; Okanoue, T.; Tanaka, Y.; Kumada, T.; Iwakiri, K.; Maeda, S.2020
Real-world use of elbasvir/grazoprevir and outcomes in patients with Chronic Hepatitis C: retrospective data analyses from the TRIO NetworkNwankwo, C.; Bacon, B.; Curry, M.; Dieterich, D.; Flamm, S.; Milligan, S.; Tsai, N.; Younossi, Z.; Afdhal, N.2018
Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort studyOgawa, E.; Furusyo, N.; Nakamuta, M.; Nomura, H.; Satoh, T.; Takahashi, K.; Koyanagi, T.; Kajiwara, E.; Dohmen, K.; Kawano, A.; Ooho, A.; Azuma, K.; Kato, M.; Shimoda, S.; Hayashi, J.2019
Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney diseaseOgawa, E.; Furusyo, N.; Azuma, K.; Nakamuta, M.; Nomura, H.; Dohmen, K.; Satoh, T.; Kawano, A.; Koyanagi, T.; Ooho, A.; Takahashi, K.; Kato, M.; Shimoda, S.; Kajiwara, E.; Hayashi, J.2018
Regression of hepatitis C virus-associated membranoproliferative glomerulonephritis with direct-acting antiviral therapy after liver transplantationOkamura, K.; Kuwabara, T.; Enoki, H.; Kohda, Y.; Adachi, M.; Hayashida, S.; Inomata, Y.; Mukoyama, M.2019
Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiencesÖrmeci , N.; Sezgin, O.; Karaali, R.; Aygen, B.; Turan, D.; Yaras, S.; Erdem,; Yildiz, O.; Karakaya, F.; Ate, K.; Asiller,2019
Treatment with pegylated interferon before transplantation improves posttransplant outcome in dialysis patients infected with HCVGulin, M.; Juki, N. B.2018
Biomarkers of minimal residual disease in rituximab treated patients with mixed cryoglobulinemiaGulli, F.; Marino, M.; Napodano, C.; Pocino, K.; Basile, V.; Marrapodi, R.; Colantuono, S.; Rapaccini, G. L.; Visentini, M.; Basile, U.2019
Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipientsGupta, G.; Yakubu, I.; Bhati, C. S.; Zhang, Y.; Kang, L.; Patterson, J. A.; Andrews-Joseph, A.; Alam, A.; Ferreira-Gonzalez, A.; Kumar, D.; Moinuddin, I. K.; Kamal, L.; King, A. L.; Levy, M.; Sharma, A.; Cotterell, A.; Reichman, T. W.; Khan, A.; Kimball, P.; Stiltner, R.; Baldecchi, M.; Brigle, N.; Gehr, T.; Sterling, R. K.2020
Efficacy and safety profile of direct-acting antiviral agents in hemodialysis patients with chronic hepatitis C infectionHanif, F.; Luck, N.; Mandhwani, R.2017
Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are ScarceHanif, F. M.; Laeeq, S. M.; Mandhwani, R. K.; Luck, N. H.; Aziz, T.; Mehdi, S. H.2017
Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in PakistanHanif, F. M.; Mandhwani, R.; Lail, G.; Luck, N. H.; Aziz, T.2019
Sofosbuvirdaclatasvir improves hepatitis C virus induced mixed cryoglobulinemia: Upper Egypt experienceHassan, A. M.; Osman, H. A.; Mahmoud, H. S.; Hassan, M. H.; Hashim, A. K. A.; Ameen, H. H.2018
Sofosbuvir-daclatasvir improves hepatitis C virus-induced mixed cryoglobulinemia: Upper Egypt experienceHassan, A. M.; Osman, H. A.; Mahmoud, H. S.; Hassan, M. H.; Hashim, A. A.; Ameen, H. H.2018
Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysisHe, Y. L.; Yang, S. J.; Hu, C. H.; Dong, J.; Gao, H.; Yan, T. T.; Liu, J. F.; Yang, Y.; Ren, D. F.; Zhu, L.; Zhao, Y. R.; Chen, T. Y.2018
DNA damage and repair in patients with cryoglobulinemic vasculitis treated with direct anti-HCV drugsHegazy, M. T.; Allam, W.; Hussein, M. A.; Zoheir, N.; Quartuccio, L.; Cacoub, P.; Doss, W.; Ellawindi, M. I.; Fawzy, M.; Guillevin, L.; El Ray, A.; Raziky, M. E. S. E.; Serafy, M. E.; Khamisy, S. E.; Ragab, G.2018
Relapsing cryoglobulinemia vasculitis following successful HCV eradication by interferon-free direct acting antivirals, an international multicenter studyHegazy, M. T.; Fayed, A.; Shabony, T. E.; Visentini, M.; Saadoun, D.; Ragab, G.; Cacoub, P.2019
Relapsing cryoglobulinemic vasculitis following successful HCV eradication by interferon-free direct acting antivirals, an international multicenter studyHegazy, M. T.; Fayed, A.; El Shabony, T.; Visentini, M.; Saadoun, D.; Cacoub, P.; Ragab, G.2019
Real-world evidence on all-oral, interferon-free regimens with Ombitasvir/Paritaprevir/r and Dasabuvir for treatment of chronic HCV patients with renal insufficiency in the German Hepatitis CRegistryHinrichsen, H.; Wiegand, J.; Schott, E.; Buggisch, P.; Gerken, G.; Heyne, R.; Lutz, T.; Ullrich, R.; Konig, B.; Hettinger, J.2016
Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infectionHogan, J. J.; Lim, M. A.; Palmer, M. B.; Bloom, R. D.; Chung, R. T.; Sise, M. E.2017
Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipientsHuang, H.; Tang, H.; Deng, H.; Shen, J.; Zhou, Q.; Xie, W.; Wu, J.; Chen, J.2019
Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and OlderHuff, J.; Andersen, R.2020
Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis CHuraib, S.; Iqbal, A.; Tanimu, D.; Abdullah, A.2001
[Hepatitis C virus-associated cryoglobulinemic vasculitis: A 20-year experience with treatment]Ignatova, T. M.; Kozlovskaya, L. V.; Gordovskaya, N. B.; Chernova, O. A.; Milovanova, S. Y.; Novikov, P. I.; Nekrasova, T. P.; Beketova, T. V.; Mukhin, N. A.2017
Management of patients with chronic kidney disease in the setting of interferon-free treatment for chronic HCV hepatitisIliescu, E. L.; Ioanitescu, S.; Toma, L.; Ureche, M. B.; Mercan-Stanciu, A.; Iancu, C.; Dodot, M.2018
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney diseaseIliescu, E. L.; Mercan-Stanciu, A.; Toma, L.2020
THE IMPACT OF OMBITASVIR/PARITAPREVIR/RITONAVIR WITH DASABUVIR IN PATIENTS WITH HCV ASSOCIATED CRYOGLOBULINEMIA- EXPERIENCE OF A SINGLE CENTERIliescu, E. L.; Grumeza, M.; Mercan, A.; Toma, L.; Dodot, M.; Isac, T.2019
The impact of ombitasvir/paritaprevir/ritonavir with dasabuvir in patients with HCV associated cryoglobulinemia-experience of a single centerIliescu, E. L.; Baciuureche, M.; Mercan, A.; Dodot, M.; Dumitru, R.; Toma, L.
Effect and safety of daclatasvir and asunaprevir combination therapy for chronic hepatitis or compensated cirrhosis by HCV genotype 1b infection in patients with renal dysfunction; From real world dataIshigami, M.; Hayashi, K.; Honda, T.; Kuzuya, T.; Ishizu, Y.; Hirooka, Y.; Goto, H.2016
Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With RenalDysfunctionIshigami, M.; Hayashi, K.; Honda, T.; Kuzuya, T.; Ishizu, Y.; Ishikawa, T.; Nakano, I.; Urano, F.; Kumada, T.; Yoshioka, K.; Goto, H.; Hirooka, Y.2017
Direct antivirus agents therapy reduce BETA2 microglobulin levels of the hemodialysis patients with hepatitis C virus infectionIto, M.2019
Virological response to daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection in dialysis patients: a prospective, multicenter studyUojima, H.2017
Direct-acting antivirals for chronic hepatitis CJakobsen, J. C.; Nielsen, E. E.; Feinberg, J.; Katakam, K. K.; Fobian, K.; Hauser, G.; Poropat, G.; Djurisic, S.; Weiss, K. H.; Bjelakovic, M.; Bjelakovic, G.; Klingenberg, S. L.; Liu, J. P.; Nikolova, D.; Koretz, R. L.; Gluud, C.2017
Hepatitis C positive donor to negative recipient kidney transplantation: A real world experienceJandovitz, N.; Nair, V.; Grodstein, E.; Molmenti, E.; Fahmy, A.; Abate, M.; Bhaskaran, M.; Teperman, L.2020
Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world studyJang, E. S.; Kim, K. A.; Kim, Y. S.; Kim, I. H.; Lee, B. S.; Lee, Y. J.; Chung, W. J.; Jeong, S. H.2020
Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in AsiaJi, F.; Wei, B.; Yeo, Y. H.; Ogawa, E.; Zou, B.; Stave, C. D.; Li, Z.; Dang, S.; Furusyo, N.; Cheung, R. C.; Nguyen, M. H.2018
Symptomatic and virological response to antiviral therapy in hepatitis C associated with extrahepatic complications of cryoglobulimiaJoshi, S.; Kuczynski, M.; Heathcote, E. J.2007
Clinical outcomes of hepatitisC virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter studyMorishita, A.; Ogawa, C.; Moriya, A.; Tani, J.; Yoneyama, H.; Fujita, K.; Oryu, M.; Senoo, T.; Takaguchi, K.; Masaki, T.2020
Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis CMousa, D. H.; Abdalla, A. H.; Al-Shoail, G.; Al-Sulaiman, M. H.; Al-Hawas, F. A.; Al-Khader, A. A.2004
Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experienceMuñoz-Gómez, R.; Rincón, D.; Ahumada, A.; Hernández, E.; Devesa, M. J.; Izquierdo, S.; Ortiz, M.; Hernández-Albujar, A.; Fernández-Rodríguez, C.; Calvo, M.; González, R.; Lozano, M.; Castellano, G.; Fernández-Vázquez, I.2017
Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-AnalysisKao, C. C.; Lin, Y. S.; Chu, H. C.; Fang, T. C.; Wu, M. S.; Kang, Y. N.2018
Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World ExperienceKapila, N.; Menon, K. V. N.; Al-Khalloufi, K.; Vanatta, J. M.; Murgas, C.; Reino, D.; Ebaid, S.; Shaw, J. J.; Agrawal, N.; Rhazouani, S.; Navas, V.; Sheffield, C.; Rahman, A. U.; Castillo, M.; Lindenmeyer, C. C.; Miller, C.; Quintini, C.; Zervos, X. B.2020
Effectiveness and safety of sofosbuvir-based therapy against chronic hepatitis C infection after successful kidney transplantationMusialik, J.; Kolonko, A.; Kwiecie, K.; Owczarek, A. J.; Wicek, A.2019
Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysisMorisawa, N.; Koshima, Y.; Kuriyama, S.; Matsuyama, M.; Hayashi, N.; Satoh, J. I.; Amemiya, M.; Yokoo, T.2017
Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting antiviral therapy without ribavirinKapila, N.; Flocco, G.; Al Khalloufi, K.; Zervos, X. B.2019
Safety and Efficacy of Pegylated Interferon Alpha-2b Monotherapy in Hepatitis C Virus-Infected Children with End-Stage Renal Disease on HemodialysisMogahed, E. A.; Abdelaziz, H.; Helmy, H.; Ghita, H.; Abdel Mawla, M. A.; Hassanin, F.; Fadel, F. I.; El-Karaksy, H.2016
Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experienceMolnar, M. Z.; Nair, S.; Cseprekal, O.; Yazawa, M.; Talwar, M.; Balaraman, V.; Podila, P. S. B.; Mas, V.; Maluf, D.; Helmick, R. A.; Campos, L.; Nezakatgoo, N.; Eymard, C.; Horton, P.; Verma, R.; Jenkins, A. H.; Handley, C. R.; Snyder, H. S.; Cummings, C.; Agbim, U. A.; Maliakkal, B.; Satapathy, S. K.; Eason, J. D.2019
Safety of Direct-Acting Antiviral Therapy for Renal Function in Post-Kidney Transplant Patients Infected with Hepatitis C Virus and a 100% 12-Week Sustained Virologic Response: A Single-Center StudyKawagishi, N.; Nakamura, A.; Takayama, T.; Haga, I.2020
Treatment for hepatitis C virus-associated mixed cryoglobulinaemiaMontero, N.; Fav, A.; Rodriguez, E.; Barrios, C.; Cruzado, J. M.; Pascual, J.; Soler, M. J.2018
Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot studyKawakami, Y.; Imamura, M.; Ikeda, H.; Suzuki, M.; Arataki, K.; Moriishi, M.; Mori, N.; Kokoroishi, K.; Katamura, Y.; Ezaki, T.; Ueno, T.; Ide, K.; Masaki, T.; Ohdan, H.; Chayama, K.2016
Efficacy and safety of glecaprevir/pibrentasvir in patients with hepatitisC virus infection aged 75yearsKinoshita, A.; Koike, K.; Mizuno, Y.; Ogata, I.; Kobayashi, Y.; Hasegawa, K.; Shiraishi, K.; Yoshida, H.; Nakata, R.; Yamada, N.; Yasuda, K.2020
Ledipasvir/sofosbuvir is effective and well tolerated in post-kidney transplant patients with chronic hepatitis C virusMorales, A.; Liriano-Ward, L. E.; Tierney, A.; Sang, M.; Lalos, A.; Hassan, M. A.; Nair, V.; Schiano, T.; Smith, C.; Satoskar, R.2016
Hepatocellular carcinoma after direct-acting antiviral drug treatment in patients with hepatitis C virusKogiso, T.; Sagawa, T.; Kodama, K.; Taniai, M.; Katagiri, S.; Egawa, H.; Yamamoto, M.; Tokushige, K.2019
Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney diseaseKohli, A.; Alshati, A.; Georgie, F.; Manch, R.; Gish, R. G.2016
Reversal of end-stage renal failure using direct-acting antiviral agents for chronic hepatitis CMitchell, T.; Chakera, A.; Jeffrey, G. P.; Adams, L. A.; Garas, G.; Jones, T.; MacQuillan, G.2016
Changes in Office Blood Pressure Control, Augmentation Index, and Liver Steatosis in Kidney Transplant Patients after Successful Hepatitis C Infection Treatment with Direct Antiviral AgentsKolonko, A.; Musialik, J.; Chudek, J.; Bartmaska, M.; Sabiak-Ba, N.; Kujawa-Szewieczek, A.; Kuczera, P.; Kwiecie-Furmaczuk, K.; Wicek, A.2020
Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohortKondili, L. A.; Monti, M.; Gaeta, G. B.; Rizzo, V.; Borgia, G.; Zappulo, E.; Chemello, L.; Cavalletto, L.; Vinci, M.; Palladini, S.; Andreone, P.; Margotti, M.; Puoti, M.; Danieli, E.; Persico, M.; Masarone, M.; Madonia, S.; Brunetto, M. R.; Coco, B.; Ieluzzi, D.; Passigato, N.; Rumi, M. G.; Sciola, V.; Massari, M.; Corsini, R.; Mazzella, G.; Lazzarini, G.; Taliani, G.; Biliotti, E.; Andreoni, M.; Cerva, C.; Alberti, A.; Gonzo, M.; Chessa, L.; Pasetto, M. C.; Federico, A.; Dallio, M.; Quaranta, M. G.; Weimer, L. E.; Vella, S.; Zignego, A. L.2017
Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney diseaseMekky, M. A.; Abdel-Malek, M. O.; Osman, H. A.; Abdel-Aziz, E. M.; Hashim, A. A.; Hetta, H. F.; Morsy, K. H.2019
Long term effectiveness of Daa therapy in patients with chronic HCV and mixed cryoglobulinemic syndromeKondili, L. A.; Monti, M.; Ferrante, G.; Quaranta, M. G.; Madia, F.; Vinci, M.; Borgia, G.; Brancaccio, G.; Coco, B.; Margotti, M.; Chemello, L.; Ciancio, A.; Rumi, M. G.; Puoti, M.; Madonia, S.; Fracanzani, A. L.; Persico, M.; Filomia, R.; Biliotti, E.; Benedetti, A.; Negri, E.; Ieluzzi, D.; Coppola, C.; Santantonio, T. A.; Zignego, A. L.2019
Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemiaMiailhes, P.; Hartig-Lavie, K.; Virlogeux, V.; Pradat, P.; Diakite, M.; Uhres, A. C.; Zoulim, F.; Sarda, M. N.2018
Hepatitis C Treatment Of Renal Transplant And Chronic Kidney Disease Patients: Efficacy And Safety Of Direct-Acting Antiviral Regimens Containing SofosbuvirMichels, F. B. L.; Amaral, A. C. C.; Carvalho-Filho, R. J.; Vieira, G. A.; Souza, Alds; Ferraz, M. L. G.2020
Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney diseaseKondo, C.; Atsukawa, M.; Tsubota, A.; Shimada, N.; Abe, H.; Asano, T.; Yoshizawa, K.; Okubo, T.; Chuganji, Y.; Aizawa, Y.; Iio, E.; Tanaka, Y.; Iwakiri, K.2017
Interleukin-17A and B-cell activating factor in chronic hepatitis c patients with or without asymptomatic mixed cryoglobulinemia: Effects of antiviral treatment and correlations with vitamin DKonstantinides, P.; Alexopoulou, A.; Hadziyannis, E.; Kanellopoulou, T.; Dourakis, S. P.2018
Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virusMisiani, R.; Bellavita, P.; Fenili, D.; Vicari, O.; Marchesi, D.; Sironi, P. L.; Zilio, P.; Vernocchi, A.; Massazza, M.; Vendramin, G.1994
Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative SubjectsKosloski, M. P.; Zhao, W.; Marbury, T. C.; Preston, R. A.; Collins, M. G.; Pugatch, D.; Mensa, F.; Kort, J.; Liu, W.2018
Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R+Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical TrialsMehta, D. A.; Cohen, E.; Charafeddine, M.; Cohen, D. E.; Bao, Y.; Sanchez Gonzalez, Y.; Tran, T. T.2017
Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare systemKramer, J. R.; Puenpatom, A.; Erickson, K. F.; Cao, Y.; Smith, D.; El-Serag, H. B.; Kanwal, F.2018
Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infectionKumada, H.; Watanabe, T.; Suzuki, F.; Ikeda, K.; Sato, K.; Toyoda, H.; Atsukawa, M.; Ido, A.; Takaki, A.; Enomoto, N.; Kato, K.; Alves, K.; Burroughs, M.; Redman, R.; Pugatch, D.; Pilot-Matias, T. J.; Krishnan, P.; Oberoi, R. K.; Xie, W.; Chayama, K.2018
Etiology of dysfunction in grafts from hepatitis c-infected donorsL'Imperio, V.; Rossi, M.; Paueksakon, P.; Kapp, M.2020
Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experienceLauletta, G.; Russi, S.; Pavone, F.; Vacca, A.; Dammacco, F.2017
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infectionLawitz, E.; Flisiak, R.; Abunimeh, M.; Sise, M. E.; Park, J. Y.; Kaskas, M.; Bruchfeld, A.; Wrns, M. A.; Aglitti, A.; Zamor, P. J.; Xue, Z.; Schnell, G.; Jalundhwala, Y. J.; Porcalla, A.; Mensa, F. J.; Persico, M.2020
Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemiaMazzaro, C.; Lacchin, T.; Moretti, M.; Tulissi, P.; Manazzone, O.; Colle, R.; Pozzato, G.1995
Efficacy and Safety of Glecaprevir/Pibrentasvir in Renallyimpaired Patients with Chronic HCV Genotype 1-6 InfectionLawitz, E.; Flisiak, R.; Abunimeh, M.; Sise, M.; Park, J. Y.; Kaskas, M.; Bruchfeld, A.; Wrns, M. A.; Aglitti, A.; Xue, Z.; Rullman, J.; Porcalla, A. R.; Cohen, E.; Trinh, R. N.; Persico, M.2018
Interferon alfa VS steroids in patients with HCV cryoglobulinemic glomerulonephritisMazzaro, C.; Panarello, G.; Faelli, A.; Donada, C.; Baracetti, S.; Zorat, F.; Nascimben, F.; Pozzato, G.1999
Mixed cryoglobulinemia, clinical data and therapy options of 246 cases: Monocentric studyMazzaro, C.; Mauro, E.; Dal Maso, L.; Ghersetti, M.; Zorat, F.; Gattei, V.; Pozzato, G.2018
Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 CasesMazzaro, C.; Maso, L. D.; Mauro, E.; Gattei, V.; Ghersetti, M.; Bulian, P.; Moratelli, G.; Grassi, G.; Zorat, F.; Pozzato, G.2018
Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemiaMaduell, F.; Belmar, L.; Ugalde, J.; Laguno, M.; Martnez-Rebollar, M.; Ojeda, R.; Arias, M.; Rodas, L.; Rossi, F.; Llovet, L. P.; Gonzlez, L. N.; Mallolas, J.; Londoo, M. C.2019
Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipientsEl Maghrabi, H. M.; Elmowafy, A. Y.; Refaie, A. F.; Elbasiony, M. A.; Shiha, G. E.; Rostaing, L.; Bakr, M. A.2019
Use of sofosbuvir based regimen in patients with end-stage renal disease and chronic hepatitis C; an open label, non-randomized, single arm, single center study from PakistanMandhwani, R.; Hanif, F. M.; Lail, G.; Luck, N. H.; Khalid, M. A.; Ul Haque, M. M.; Laeeq, S. M.; Aziz, T.2020
Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney diseaseManoj, Kumar; Nayak, S. L.; Gupta, E.; Kataria, A.; Sarin, S. K.2018
Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantationMansour, M.; Hill, L.; Kerr, J.2018
B-Cell depletion therapy with rituximab in patients with hepatitis C virus mixed cryoglobulinemic vasculitis improves B- and T-Cell phenotype and functionMathur, P.; Emmanuel, B.; Kottilil, S.2017
Recovery of hepatitis C specific T-cell responses after rituximab therapy in hepatitis C mixed cryoglobulinemic vasculitisMathur, P.; Emmanuel, B.; Sneller, M.; Zhang, X.; Poonia, B.; Kottilil, S.2018
Long-term results regarding the interferon alpha-2b in the treatment essential cryoglobulinemiaLauta, V. M.; De, S. A.1995
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney DiseaseLawitz, E.; Gane, E.; Cohen, E.; Vierling, J.; Agarwal, K.; Hassanein, T.; Mantry, P. S.; Pockros, P. J.; Bennett, M.; Kemmer, N.; Morelli, G.; Zha, J.; Wang, D.; Shulman, N. S.; Cohen, D. E.; Reddy, K. R.2019
Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on HemodialysisLee, B. S.; Song, M. J.; Kwon, J. H.; Lee, T. H.; Jang, J. W.; Kim, S. H.; Lee, S. H.; Kim, H. S.; Kim, J. H.; Kim, S. B.; Ko, S. Y.; Song, D. S.2019
Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysisLi, M.; Chen, J.; Fang, Z.; Li, Y.; Lin, Q.2019
Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysisLi, T.; Qu, Y.; Guo, Y.; Wang, Y.; Wang, L.2017
Add-on neurological benefits of antiviral therapy in HCV patients with chronic kidney disease - a nationwide cohort studyLin, M. S.; Chen, T. H.; Lin, W. Y.; Liu, C. H.; Hsieh, Y. Y.; Chiu, W. N.; Chang, C. H.; Chen, M. Y.; Chung, C. M.; Lin, Y. S.2017
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus InfectionLin, M. V.; Sise, M. E.; Pavlakis, M.; Amundsen, B. M.; Chute, D.; Rutherford, A. E.; Chung, R. T.; Curry, M. P.; Hanifi, J. M.; Gabardi, S.; Chandraker, A.; Heher, E. C.; Elias, N.; Riella, L. V.2016
A pilot study in comparing the efficacy and safety of peginterferon alfa-2a and interferon alfa-2a in treating patients with end stage renal disease and chronic hepatitis CLiu, C. H.2005
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysisLiu, C. H.; Peng, C. Y.; Fang, Y. J.; Kao, W. Y.; Yang, S. S.; Lin, C. K.; Lai, H. C.; Su, W. P.; Fang, S. U.; Chang, C. C.; Su, T. H.; Liu, C. J.; Chen, P. J.; Chen, D. S.; Kao, J. H.2020
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairmentLiu, C. H.; Yang, S. S.; Peng, C. Y.; Lin, W. T.; Liu, C. J.; Su, T. H.; Tseng, T. C.; Chen, P. J.; Chen, D. S.; Kao, J. H.2020
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysisLiu, C. H.; Shih, Y. L.; Yang, S. S.; Lin, C. L.; Fang, Y. J.; Cheng, P. N.; Chen, C. Y.; Peng, C. Y.; Hsieh, T. Y.; Chiu, Y. C.; Su, T. H.; Liu, C. J.; Yang, H. C.; Chen, P. J.; Chen, D. S.; Kao, J. H.2019
Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infectionLlenas-Garca, J.; Padilla, S.; Masi, M.; Gutirrez, F.2018
Effectiveness, safety/tolerability of OBV/PTV/r DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD studyLondoño, M. C.; Riveiro-Barciela, M.; Ahumada, A.; Muñoz-Gomez, R.; Roget, M.; Devesa-Medina, M. J.; Serra, M. A.; Navascues, C. A.; Baliellas, C.; Aldamiz-Echevarria, T.; Gutierrez, M. L.; Polo-Lorduy, B.; Carmona, I.; Benlloch, S.; Bonet, L.; Garcia-Samaniego, J.; Jiminez-Perez, M.; Moran-Sanchez, S.; Castro, A.; Delgado, M.; Gea-Rodriguez, F.; Martin-Granizio, I.; Montes, M. L.; Morano, L.; Castaño, M. A.; de Los Santos, I.; Laguno, M.; Losa, J. E.; Montero-Alonso, M.; Rivero, A.; de Alvaro, C.; Manzanares, A.; Mallolas, J.; Barril, G.; Gonzalez-Parra, E.; Garcia-Buey, L.2019
Mixed cryoglobulinemia patients with persisting symptoms after SVR are characterized by B-cell clonality markersLorini, S.; Gragnani, L.; Santarlasci, V.; Monti, M.; Basile, U.; Petraccia, L.; Madia, F.; Marri, S.; Martini, L.; Carradori, E.; Xheka, A.; Caini, P.; Pellicelli, A.; Cosmi, L.; Annunziato, F.; Zignego, A. L.2019
Mixed cryoglobulinemia patients with persisting symptoms after SVR are characterized by B-cell clonality markersLorini, S.; Gragnani, L.; Santarlasci, V.; Monti, M.; Basile, U.; Petraccia, L.; Madia, F.; Marri, S.; Martini, L.; Carradori, E.; Xheka, A.; Caini, P.; Pellicelli, A. M.; Cosmi, L.; Annunziato, F.; Zignego, A. L.2019
Efficacy and safety of sofosbuvir and velpatasvir in renal transplant recipients with chronic hepatitis c virus infectionGreco R; et al.2019
Treatment of chronic viral hepatitis "C" with sofosbuvir-ledipasvir in patients with dialysis-dependent chronic kidney diseaseAsanbek kyzy, A2019
Egyptian Experience of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular HemodialysisEl-Raey, F; Mansour H; El-Gendy, N; Hegazy, M; Zaky, S2019
Hepatitis C virus can be eliminated from a prevalent kidney transplant recipient population: a single-centre study in the direct-acting antivirals eraDevresse A; et al.2019
HCV infection in nephrology: screening and management in nephropathic outpatients. A 36 months experienceGernone G; et al.2019
Better blood pressure control in hcv-infected kidney transplant recipients after effective treatment with direct antiviral agentsKolonko A; et al,2019
Direct acting antivirals are effective and safe in HCV positive kidney transplant recipients (KTRs), even with advanced liver fibrosisPaoletti E; et al.2019
Effectiveness and safety of DAA-based treatment of hepatitis C patients with severe and end stage chronic kidney diseases-EpiTer-2 database analysisTomasiewicz K; et al.2019
Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal DiseaseChuang, W-L; Hu, Tsung-Hui; Buggisch, Peter ; Moreno, Christophe ; Su, Wei-Wen; Biancone, Luigi; Camargo, Marianne; Dvory-Sobol, Hadas; Hyland, Robert; Kirby, Brian J.; Lu, Sophia; Osinusi, Anu; Gaggar, Anuj; Liu, Chen-Hua; Mangia, Alessandra; Peng, Cheng-Yuan; Sise, Meghan E.2021
Prospective multicenter study of sofosbuvir-velpatasvir (SOF/VEL) in hepatitis C virus (HCV) negative liver (LT) and kidney transplant (KT) recipients receiving HCV viremic donorsRubin R; et al.2020
An open-label, cohort study of grazoprevir/elbasvir combination therapy for patients with genotype 1b chronic hepatitis C after liver or kidney transplantationLee T-Y; et al.2020
Kidney transplant from hepatitis C positive donors to hepatitis C negative recipients: report on the first experience in the UKHealy B; et al.2020
Grazoprevir/elbasvir for treatment of hepatitis C virus genotype 4 post kidney transplantAbaalkhail F; et al.2020
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease - data from the German hepatitis C-registry (DHC-R)Stein K; et al.2020
Risk of end-stage renal disease among hepatitis C patients with chronic kidney disease treated with and without sofosbuvirTelep L; et al.2020
Direct Acting Antiviral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C-Negative Kidney Transplant RecipientsYakubu I; et al.2020
First year renal outcome of transplantations of kidneys from hepatitis c infected donors to hepatitis c negative recipientsMolnar, M.Z.; et al.2020
Impact of hepatitis c virus and direct acting antivirals on Japanese renal allograft recipientsOkino, K.; et al.2020
Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease.Bhamidimarri, Kalyan Ram; Czul, Frank; Peyton, Adam; Levy, Cynthia; Hernandez, Maria; Jeffers, Lennox; Roth, David; Schiff, Eugene; O'Brien, Christopher; Martin, Paul2015
New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.Mawatari, Seiichi; Oda, Kohei; Tabu, Kazuaki; Ijuin, Sho; Kumagai, Kotaro; Inada, Yukiko; Uto, Hirofumi; Hiramine, Yasunari; Kure, Takeshi; Fujisaki, Kunio; Hashiguchi, Masafumi; Hori, Takeshi; Oshige, Akihiko; Imanaka, Dai; Saishoji, Akiko; Taniyama, Oki; Sakae, Haruka; Tamai, Tsutomu; Moriuchi, Akihiro; Ido, Akio2017
Transplantation of Kidneys from Hepatitis C-Infected Donors to Hepatitis C-Negative Recipients: 1-Year Renal Allograft OutcomesMolnar, MZ; et al.2020
Hepatitis C NAT-Positive Kidney Transplant into Hepatitis C-Negative Recipients: A Single-Center ExperienceKaur T; et al.2020
Experience with Directly Acting Antiviral Agents for Hepatitis C in Maintenance Hemodialysis Patients in a Single Center from PakistanRashid RM; et al.2019
Preemptive treatment with grazoprevir and elbasvir for donor hcv viremic donors to hcv negative recipient kidney transplantationSise M; et al.2019
Directly acting anti-viral agents improve health related quality of life in chronic hepatitis c patients with chronic kidney diseaseSinghal R; et al.2019
Hepatitis C viremic organs transplanted into nonviremic recipients; a real world nurse practitioner led clinicParkinson E; et al.2020
8 weeks versus 12 weeks of direct-acting antiviral therapy for kidney transplant recipients with chronic hepatitis C infectionCioffi J; et al.2020
Comedications and their potential drug-drug interactions with direct-acting antiviral agents in hepatitis C patients on hemodialysisHsu P-Y; et al.2020
Establishment of an outreach, grouping health care system with sofosbuvir/velpatasvir to achieve micro-elimination of HCV in hemodialysis centers (ERASE-C)Yu M-L; et al.2020
Long-term post-operative outcomes, waitlist times, and treatment results of hepatitis c negative liver, kidney, and simultaneous liver-kidney transplant recipients with hepatitis C positive donorsRay J; et al.2020
Treatment efficacy and safety of sofosbuvir with velpatasvir for chronic hepatitis C among uremic patients under maintenance hemodialysis-an interim report of ERASE-CYu M-L; et al.2020
Treatment efficacy and safety of sofosbuvir/velpatasvir for chronic hepatitis C among uremic patients under maintenance hemodialysis-an interim report of ERASE-CYu M-L; et al.2020
Sofosbuvir plus Velpatasvir combination is safe and effective in treating chronic hepatitis C in patients with end stage renal disease (ESRD).Duseja, A.; et al.2020
Assessment of liver fibrosis using APRI score after treatment with elbasvir/grazoprevir in patients with hepatitis C infection and chronic kidney disease on hemodialysisBayu, L; et al.2020
Changes of liver fibrosis in chronic hepatitis C patients with chronic kidney disease who had undergone hemodialysis after DAA therapySuryamin M; et al.2020
Elbasvir (EBR)/grazoprevir (GZR) is effective and tolerable for the treatment of HCV GT1-infected patients: a real world multicenter observatory study in TaiwanLiu C-J; et al.2020
Sofosbuvir/Velpatasvir for 12 weeks is safe and effective in patients undergoing dialysisBorgia SM; et al.2019
Use of Glecaprevir/Pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairmentYap D Y-H; et al.2019
Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC studyPérez de José, A; Carbayo, J; Pocurull, A; Bada-Bosch, T; Cases Corona, CM; Shabaka, A; Ramos Terrada, N; Martinez Valenzuela, L; Huerta, A; Fernandez Lorente, L; Gelen Malek-Marín, T; Goicoechea, M2021
Transplantation of Renal Allografts From Organ Donors Reactive for HCV Antibodies to HCV-Negative Recipients: Safety and Clinical Outcome.Nowak Knut Michael; Witzke Oliver; Sotiropoulos Georgios C; Benkö Tamas; Fiedler Melanie; Timm Jörg; Kribben Andreas; Wilde Benjamin; Saner Fuat; Paul Andreas; Treckmann Jürgen2017
Impact of Willingness to Accept Hepatitis C Seropositive Kidneys Among Hepatitis C RNA-Positive Waitlisted Patients.Sageshima Junichiro; Troppmann Christoph; McVicar John P; Santhanakrishnan Chandrasekar; de Mattos Angelo M; Perez Richard V2018
Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: Analysis of United States national data.Gupta Gaurav; Kang Le; Yu Jonathan W; Limkemann Ashley J; Garcia Victoria; Bandyopadhyay Dipankar; Kumar Dhiren; Fattah Hasan; Levy Marlon; Cotterell Adrian H; Sharma Amit; Bhati Chandra; Reichman Trevor; King Anne L; Sterling Richard2017
Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals.La Hoz Ricardo M; Sandıkçı Burhaneddin; Ariyamuthu Venkatesh K; Tanriover Bekir2019
Use of Organs From Hepatitis C Virus-Positive Donors for Uninfected Recipients: A Potential Cost-Effective Approach to Save Lives?Trotter Patrick B; Summers Dominic M; Ushiro-Lumb Ines; Robb Matthew; Bradley J Andrew; Powell James; Watson Christopher J E; Neuberger James2018
Effect of Recipient Hepatitis C Status on Outcomes of Deceased Donor Kidney Transplantation.Yuan Qing; Hong Shanjuan; Perez-Ortiz Andric; Roth Eve; Chang David C; Madsen Joren C; Elias Nahel2020
Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation.Sise Meghan E; Strohbehn Ian A; Chute Donald F; Gustafson Jenna; Van Deerlin Vivianna M; Smith Jennifer R; Gentile Caren; Wojciechowski David; Williams Winfred W; Elias Nahel; Chung Raymond T2020
Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.Friebus-Kardash Justa; Gäckler Anja; Kribben Andreas; Witzke Oliver; Wedemeyer Heiner; Treckmann Jürgen; Herzer Kerstin; Eisenberger Ute2019
Patient's Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single Site.Van Pilsum Rasmussen Sarah E; Seaman Shanti; Brown Diane; Desai Niraj; Sulkowski Mark; Segev Dorry L; Durand Christine M; Sugarman Jeremy2020 Jan-Mar
Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States.Bowring Mary G; Shaffer Ashton A; Massie Allan B; Cameron Andrew; Desai Niraj; Sulkowski Mark; Garonzik-Wang Jacqueline; Segev Dorry L2019
Process of selecting and educating HCV-uninfected kidney waiting-list candidates for HCV-infected kidney transplantation.Sise Meghan E; Wojciechowski David; Chute Donald F; Gustafson Jenna; Chung Raymond T; Williams Winfred W; Elias Nahel2019
Treatment of hepatitis C-virus-related glomerulonephritis.Kamar N; Rostaing L; Alric L2006
Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD.Sise ME; Backman E; Ortiz GA; Hundemer GL; Ufere NN; Chute DF; Brancale J; Xu D; Wisocky J; Lin MV; Kim AY; Thadhani R; Chung RT2017 Oct 6
Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment.Suda G; Nagasaka A; Yamamoto Y; Furuya K; Kumagai K; Kudo M; Terashita K; Kobayashi T; Tsunematsu I; Yoshida J; Meguro T; Kimura M; Ito J; Umemura M; Izumi T; Tsunematsu S; Sato F; Tsukuda Y; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N2017 Oct
Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.Sise ME; Bloom AK; Wisocky J; Lin MV; Gustafson JL; Lundquist AL; Steele D; Thiim M; Williams WW; Hashemi N; Kim AY; Thadhani R; Chung RT2016 Feb
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.Roth D; Nelson DR; Bruchfeld A; Liapakis A; Silva M; Monsour H Jr; Martin P; Pol S; Londono MC; Hassanein T; Zamor PJ; Zuckerman E; Wan S; Jackson B; Nguyen BY; Robertson M; Barr E; Wahl J; Greaves W2015 Oct 17
Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study.Quartuccio L; Zuliani F; Corazza L; Scaini P; Zani R; Lenzi M; Tavoni A; Sebastiani M; Baldovino S; Urraro T; Saccardo F; Sbreglia C; Mazzaro C; Pioltelli P; Fraticelli P; Filippini D; Gabrielli A; Perrella O; Scarpato S; Roccatello D; Zignego AL; Ferri C; Bombardieri S; Pietrogrande M; Monti G; Galli M; De Vita S2015 Sep
Efficacy and safety of pegylated interferon plus ribavirin for the treatment of hepatitis C virus-positive cryoglobulinemic glomerulonephritis.Mazzaro C; Panarello G; Mauro E; Gattei V; Pozzato G2015 Jul
Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts.Scalea JR; Barth RN; Munivenkatappa R; Philosophe B; Cooper M; Whitlow V; LaMattina JC2015 Jun
The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience.Singh N; Neidlinger N; Djamali A; Leverson G; Voss B; Sollinger HW; Pirsch JD2012 Sep-Oct
Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study.Mazzaro C; Monti G; Saccardo F; Zignego AL; Ferri C; De Vita S; Gabrielli A; Lenzi M; Donada C; Galli M; Pietrogrande M; Pozzato G2011 Nov-Dec
A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.Sneller MC; Hu Z; Langford CA2012 Mar
Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.Saadoun D; Resche Rigon M; Sene D; Terrier B; Karras A; Perard L; Schoindre Y; Coppere B; Blanc F; Musset L; Piette JC; Rosenzwajg M; Cacoub P2010 Jul 22
Effect of antiviral therapy on hepatitis C virus related glomerulopathy.Abbas G; Hussain S; Shafi T2008 Sep
Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.Saadoun D; Resche-Rigon M; Thibault V; Piette JC; Cacoub P2006 Nov
Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients.Basse G; Ribes D; Kamar N; Mehrenberger M; Sallusto F; Esposito L; Guitard J; Lavayssière L; Oksman F; Durand D; Rostaing L2006
Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.Quartuccio L; Soardo G; Romano G; Zaja F; Scott C A; De Marchi G; Fabris M; Ferraccioli G; De Vita S2006
Efficacy and safety of rituximab in type II mixed cryoglobulinemia.Zaja Francesco; De Vita Salvatore; Mazzaro Cesare; Sacco Stefania; Damiani Daniela; De Marchi Ginevra; Michelutti Angela; Baccarani Michele; Fanin Renato; Ferraccioli Gianfranco2003
Real‐life efficacy and safety of glecaprevir/pibrentasvir in HCV‐infected patients with chronic kidney diseasePersico, M; Aglitti, A; Caruso, R; Calvanese, G; Di Siervi, P; Masarone, M2019
‘Real-Life’ Experience With Direct-Acting Antiviral Agents For HCV After Kidney TransplantFabrizi Fabrizio; Alonso Cristina; Palazzo Ana; Anders Margarita; Reggiardo Maria Virginia; Cheinquer Hugo; Zuain Maria Grazia Videla; Figueroa Sebastian; Mendizabal Manuel; Silva Marcelo; Ridruejo Ezequiel; Latin American Liver Research, Educational and Awareness Network (LALREAN)2021
Transplantation of Kidneys From Hepatitis C Virus-Infected Donors to Hepatitis C Virus-Negative Recipients: One-Year Kidney Allograft Outcomes.Molnar, Miklos Z; Azhar, Ambreen; Tsujita, Makoto; Talwar, Manish; Balaraman, Vasanthi; Bhalla, Anshul; Podila, Pradeep S B; Kothadia, Jiten; Agbim, Uchenna A; Maliakkal, Benedict; Satapathy, Sanjaya K; Kovesdy, Csaba P; Nair, Satheesh; Eason, James D2021
Characterization of early hepatic injury in HCV-negative recipients of HCV-infected kidneys.Mazur, Rafal D; Abt, Peter L; Blumberg, Emily A; Bloom, Roy D; Reddy, K Rajender; Reese, Peter P; Goldberg, David S2019
Transplanting hepatitis C virus-infected hearts into uninfected recipients: A single-arm trial.McLean, Rhondalyn C; Reese Peter P; Acker Michael; Atluri Pavan; Bermudez Christian; Goldberg Lee R; Abt Peter L; Blumberg Emily A; Van Deerlin Vivianna M; Reddy K Rajender; Bloom Roy D; Hasz Richard; Suplee Lawrence; Sicilia Anna; Woodards Ashley; Zahid Muhammad Nauman; Bar Katharine J; Porrett Paige; Levine Matthew H; Hornsby Nicole; Gentile Caren; Smith Jennifer; Goldberg David S2019
Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks Is Safe and Effective in Patients Undergoing DialysisChuang, W-L; et al.2019
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.Liu Chen-Hua; Chen Chi-Yi; Su Wei-Wen; Tseng Kuo-Chih; Lo Ching-Chu; Liu Chun-Jen; Chen Jyh-Jou; Peng Cheng-Yuan; Shih Yu-Lueng; Yang Sheng-Shun; Huang Chia-Sheng; Huang Ke-Jhang; Chang Chi-Yang; Tsai Ming-Chang; Kao Wei-Yu; Fang Yo-Jen; Chen Po-Yueh; Su Pei-Yuan; Tseng Chih-Wei; Huang Jow-Jyh; Lee Pei-Lun; Lai Hsueh-Chou; Hsieh Tsai-Yuan; Chang Chung-Hsin; Huang Yi-Jie; Lee Fu-Jen; Chang Chun-Chao; Kao Jia-Horng2021
Treatment efficacy and tolerability of Sofosbuvir and Ribavirin for chronic hepatitis C infection in post renal transplant patients – A retrospective single centre studyKirushnan, B; Shujauddin, MA; Arumugam, K; Ravichandran, R2016
Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients.Duerr Michael; Liefeldt Lutz; Friedersdorff Frank; Choi Mira; Öllinger Robert; Hofmann Jörg; Budde Klemens; Schrezenmeier Eva; Halleck Fabian2020
Deferred direct-acting antiviral treatment in kidney transplantation from HCV-viremic donors into HCV-negative recipientsPagano, G; Solà, E; Cańeta, N; Broquetas, T; Carrión, JA; Puigvehí, M; Coll, S; Garrido, E; Viu, A; Romero, J; Pérez, MJ; Zapatero, A; Bessa, X; Crespo Barrio, M; Garcia-Retortillo, M2021
Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection.Miyasaka Akio; Yoshida Yuichi; Murakami Akihiko; Hoshino Takao; Sawara Kei; Numao Hiroshi; Takikawa Yasuhiro2022
Impact of Direct Acting Antiviral Agents on kidney function in Hepatitis C Virus infected patients with chronic kidney diseaseSarhan, II; Mohamed OM; Hebah, HA; Ahmed, OA; Khedr, LE; Mahmoud, WA2021
Full dose Sofosbuvir-Velpatasvir in chronic Hepatitis C in patients with end stage renal diseaseAshraf, A; Shah, A; Khan, M; Maqsood Wani, M; Gulzar, GM; Singh, J; Parveen, S; Ahmad, N; Dar, H; Abdul Aziz, R; Dhar, N; Mushfiq Shafi, S; Tiwari, A2021
Long term follow-up in HCV infected patients with end stage chronic kidney disease after DAA therapyMartinez-Camprecios, J; Muńoz Gómez, R; Londońo, MC; Roget, M; Serra, M; Escudero-Garcia, D; Puchades, L; Rodríguez, M; Losa-Garcia, JE; Gutierrez, ML; Carmona, I; Garcia-Samaniego Rey, FJ; Morano Amado, LE2021
Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan.Hu Tsung-Hui; Su Wei-Wen; Yang Chi-Chieh; Yang Chih-Chao; Kuo W-Hsien; Chen Yang-Yuan; Yeh Yung-Hsiang; Chen Shiou-Shiang; Tsao Yu-Yu; Chen Kwei-Ming; Yan Sheng-Lei; Lai Jun-Hung; Yao Chih-Da; Lim Cherng-Harng; Jen Hsiao Hsuan; Yeh Yen-Po; Chen Sam Li-Sheng; Chen Hsiu-Hsi; Chen Shih-Chung; Changhua Hepatitis C Elimination Task Force2021
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR).Huang Chung-Feng; Tseng Kuo-Chih; Cheng Pin-Nan; Hung Chao-Hung; Lo Ching-Chu; Peng Cheng-Yuan; Bair Ming-Jong; Yeh Ming-Lun; Chen Chien-Hung; Lee Pei-Lun; Lin Chun-Yen; Kuo Hsing-Tao; Chen Chun-Ting; Yang Chi-Chieh; Huang Jee-Fu; Tai Chi-Ming; Hu Jui-Ting; Lin Chih-Lang; Su Wei-Wen; Tsai Wei-Lun; Huang Yi-Hsiang; Cheng Chien-Yu; Lin Chih-Lin; Wang Chia-Chi; Yang Sheng-Shun; Mo Lein-Ray; Chen Guei-Ying; Chang Chun-Chao; Wang Szu-Jen; Huang Chia-Sheng; Hsieh Tsai-Yuan; Lin Chih-Wen; Lee Tzong-Hsi; Chong Lee-Won; Huang Chien-Wei; Chang Shiuh-Nan; Tsai Ming-Chang; Hsu Shih-Jer; Kao Jia-Horng; Liu Chun-Jen; Liu Chen-Hua; Lin Han-Chieh; Lee Mei-Hsuan; Tsai Pei-Chien; Dai Chia-Yen; Chuang Wan-Long; Chen Chi-Yi; Yu Ming-Lung2021
Direct-acting antivirals improve kidney function in diabetic patients with HCV infection and chronic kidney disease.Villani Rosanna; Romano Antonino Davide; Sangineto Moris; Serviddio Gaetano2021
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort.Calvaruso Vincenza; Petta Salvatore; Cacciola Irene; Cabibbo Giuseppe; Cartabellotta Fabio; Distefano Marco; Scifo Gaetano; Di Rosolini Maria Antonietta; Russello Maurizio; Prestileo Tullio; Madonia Salvatore; Malizia Giuseppe; Montineri Arturo; Digiacomo Antonio; Licata Anna; Benanti Francesco; Bertino Gaetano; Enea Marco; Battaglia Salvatore; Squadrito Giovanni; Raimondo Giovanni; Cammà Calogero; Craxì Antonio; Di Marco Vito; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV)2021
Genetic Association of Hepatitis C-Related Mixed Cryoglobulinemia: A 10-Year Prospective Study of Asians Treated with Antivirals.Chang Ming-Ling; Chang Su-Wei; Chen Shiang-Chi; Chien Rong-Nan; Hsu Chia-Lin; Chang Ming-Yu; Fann Cathy S J2021
Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life.Gragnani Laura; Lorini Serena; Marri Silvia; Vacchi Caterina; Madia Francesco; Monti Monica; Ferri Clodoveo; Zignego Anna Linda2022
Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis.Gragnani Laura; Lorini Serena; Marri Silvia; Basile Umberto; Santarlasci Veronica; Monti Monica; Madia Francesco; Petraccia Luisa; Stasi Cristina; Marello Niccolò; Napodano Cecilia; Annunziato Francesco; Zignego Anna Linda2021
High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b.Ji Fanpu; Li Jie; Liu Li; Liang Jing; Wang Xiaozhong; Liu Junping; Cai Dachuan; Huang Rui; Zhang Jiajie; Wang Qi; Nan Yuemin; Li Junyi; Ye Qing; Zhang Mingyuan; Xu Qiang; Guo Feng; Zhao Changqing; Liu Lingdi; He Caini; Li Yu; Wang Wenjun; Kam Leslie Y; Tran Sally; Maeda Mayumi; Mizuta Akiko; Li Zongfang; Dang Shuangsuo; Ren Wanhua; Zhu Qiang; Cheung Ramsey; Niu Junqi; Xie Wen; Pan Hongying; Ren Hong; Wu Chao; Shang Jia; Wang Fengmei; Nguyen Mindie H2021
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.Liu Chen-Hua; Chen Chi-Yi; Su Wei-Wen; Liu Chun-Jen; Lo Ching-Chu; Huang Ke-Jhang; Chen Jyh-Jou; Tseng Kuo-Chih; Chang Chi-Yang; Peng Cheng-Yuan; Shih Yu-Lueng; Huang Chia-Sheng; Kao Wei-Yu; Yang Sheng-Shun; Tsai Ming-Chang; Wu Jo-Hsuan; Chen Po-Yueh; Su Pei-Yuan; Hwang Jow-Jyh; Fang Yu-Jen; Lee Pei-Lun; Tseng Chi-Wei; Lee Fu-Jen; Lai Hsueh-Chou; Hsieh Tsai-Yuan; Chang Chun-Chao; Chang Chung-Hsin; Huang Yi-Jie; Kao Jia-Horng2021
Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study.Su Pei-Yuan; Chen Yang-Yuan; Lai Jun-Hung; Chen Hung-Ming; Yao Chih-Ta; Liu I-Ling; Zeng Ya-Huei; Huang Siou-Ping; Hsu Yu-Chun; Wu Shun-Sheng; Siao Fu-Yuan; Yen Hsu-Heng2021
Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan.Yamana Yoichiro; Kanda Tatsuo; Matsumoto Naoki; Honda Masayuki; Kumagawa Mariko; Sasaki Reina; Kanezawa Shini; Mizutani Taku; Yamagami Hiroaki; Masuzaki Ryota; Ishii Tomotaka; Nirei Kazushige; Moriyama Mitsuhiko2021
Transplantation of Hepatitis C-Infected Kidneys into Uninfected Recipients: A Review of the Literature.Leesley Haley; Osband Adena J2021
Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: A systematic review and meta-analysis.De Arka; Roy Akash; Verma Nipun; Mishra Saurabh; Premkumar Madhumita; Taneja Sunil; Singh Virendra; Duseja Ajay2022
An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease.Majd Jabbari Sara; Maajani Khadije; Merat Shahin; Poustchi Hossein; Sepanlou Sadaf G2021
Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.Ji Qinghua; Chu Xudong; Zhou Yugui; Liu Xuan; Zhao Wei; Ye Wei2022
Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.Li Chunhong; Liang Jing; Xiang Huiling; Chen Haiyan; Tian Jie2020
The outcome of Daclatasvir and low dose Sofosbuvir therapy in end-stage renal disease patients with hepatitis C virus infectionMostafi M; Jabin M; Chowdhury Z; Khondoker M; Ali S; Tamanna R; Rezwan R; Alomgir S2022
Treatment outcomes of sofosbuvir and velpatasvir in chronic hepatitis C patients undergoing hemodialysisHussain, R; Butt, N; Rai, L; Ali, S; Khemani, H; Ullah, A2021
Establishment of an outreach, grouping health care system to achieve micro-elimination of HCV for uremic patients in hemodialysis centers (ERASE-C)Huang, C-F2021
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan.Cheng Pin-Nan; Mo Lein-Ray; Chen Chun-Ting; Chen Chi-Yi; Huang Chung-Feng; Kuo Hsing-Tao; Lo Ching-Chu; Tseng Kuo-Chih; Huang Yi-Hsiang; Tai Chi-Ming; Peng Cheng-Yuan; Bair Ming-Jong; Chen Chien-Hung; Yeh Ming-Lun; Lin Chih-Lang; Lin Chun-Yen; Lee Pei-Lun; Chong Lee-Won; Hung Chao-Hung; Chang Te Sheng; Huang Jee-Fu; Yang Chi-Chieh; Hu Jui-Ting; Lin Chih-Wen; Wang Chia-Chi; Su Wei-Wen; Hsieh Tsai-Yuan; Lin Chih-Lin; Tsai Wei-Lun; Lee Tzong-Hsi; Chen Guei-Ying; Wang Szu-Jen; Chang Chun-Chao; Yang Sheng-Shun; Wu Wen-Chih; Huang Chia-Sheng; Chou Kwok-Hsiung; Kao Chien-Neng; Tsai Pei-Chien; Liu Chen-Hua; Lee Mei-Hsuan; Cheng Chien-Yu; Tsai Ming-Chang; Liu Chun-Jen; Dai Chia-Yen; Lin Han-Chieh; Kao Jia-Horng; Chuang Wan-Long; Yu Ming-Lung; TACR investigators2022
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).Yu Ming-Lung; Huang Chung-Feng; Wei Yu-Ju; Lin Wen-Yi; Lin Yi-Hung; Hsu Po-Yao; Hsu Cheng-Ting; Liu Ta Wei; Lee Jia-Jung; Niu Sheng-Wen; Huang Jiun-Chi; Hung Tzu-Sui; Yeh Ming-Lun; Huang Ching-I; Liang Po-Cheng; Hsieh Ming-Yen; Chen Szu-Chia; Huang Jee-Fu; Chang Jer-Ming; Chiu Yi-Wen; Dai Chia-Yen; Hwang Shang-Jyh; Chuang Wan-Long; FORMOSA-LIKE investigators2021
Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection.Lai Ping-Chin; Chen Cheng-Hsu; Jeng Long-Bin; Yu Tung-Min; Tsai Shang-Feng; Wu Ming-Ju; Cheng Shao-Bin; Yang Sheng-Shun; Lee Teng-Yu2022
12 weeks treatment of Sofosbuvir/Velpatasvir in HCV negative recipients receiving renal transplantation from HCV positive donorsChen, R; Li, D; Zhuang, S; Zhang, M; Yuan, X2021
Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors.Chen Ruoyang; Li Dawei; Zhang Ming; Yuan Xiaodong2021
Kidney Transplantation From Hepatitis C Viremic Deceased Donors to Aviremic Recipients in a Real-world Setting.Concepcion Beatrice P; Binari Laura A; Schaefer Heidi; Rega Scott; Feurer Irene; Shawar Saed; Naik Ruchi; Hickman Laura; Walker Jasmine; Kapp Meghan; Birdwell Kelly A; Langone Anthony; Helderman J Harold; Ann Sarrell Bonnie; Kochar Guneet; Dubray Bernard; Smith Kristin; O'Dell Heather; DeMers April; Shelton Princess; Perri Roman; Shaffer David; Forbes Rachel C2021
Outcomes of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants.Gupta Gaurav; Yakubu Idris; Zhang Yiran; Kimball Pamela; Kang Le; Mitchell Kimberly; Ijioma Stephen; Carroll Norman; Patterson Julie; Shinbashi Meagan; Kumar Dhiren; Moinuddin Irfan; Kamal Layla; King Anne; Bhati Chandra; Levy Marlon; Cotterell Adrian; Khan Aamir; Sharma Amit; Sterling Richard2021
A real-world, single-center experience of the utilization of hepatitis C-viremic kidneys for hepatitis C-negative recipients.Daloul Reem; Anthony Michaels; Washburn Kenneth; Singh Priyamvada; Pesavento Todd2021
Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study.Tronina Olga; Durlik Magdalena; Orłowska Iwona; Lorenc Beata; Łapiński Tadeusz W; Garlicki Aleksander; Dybowska Dorota; Zarębska-Michaluk Dorota; Tudrujek-Zdunek Magdalena; Citko Jolanta; Janczewska Ewa; Kaczmarczyk Marcin; Jaroszewicz Jerzy; Krygier Rafał; Klapaczyński Jakub; Dobracka Beata; Białkowska-Warzecha Jolanta; Piekarska Anna; Simon Krzysztof; Halota Waldemar; Pawłowska Małgorzata; Tomasiewicz Krzysztof; Flisiak Robert2021
Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct-acting antiviral initiation.Hudson Madeline R; Webb Allyssa R; Logan Angela Tong; Silverman Andrew; Brueckner Andrew J2021
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.Lo Ching-Chu; Huang Chung-Feng; Cheng Pin-Nan; Tseng Kuo-Chih; Chen Chi-Yi; Kuo Hsing-Tao; Huang Yi-Hsiang; Tai Chi-Ming; Peng Cheng-Yuan; Bair Ming-Jong; Chen Chien-Hung; Yeh Ming-Lun; Lin Chih-Lang; Lin Chun-Yen; Lee Pei-Lun; Chong Lee-Won; Hung Chao-Hung; Chang Te Sheng; Huang Jee-Fu; Yang Chi-Chieh; Hu Jui-Ting; Lin Chih-Wen; Chen Chun-Ting; Wang Chia-Chi; Su Wei-Wen; Hsieh Tsai-Yuan; Lin Chih-Lin; Tsai Wei-Lun; Lee Tzong-Hsi; Chen Guei-Ying; Wang Szu-Jen; Chang Chun-Chao; Mo Lein-Ray; Yang Sheng-Shun; Wu Wen-Chih; Huang Chia-Sheng; Hsiung Chou-Kwok; Kao Chien-Neng; Tsai Pei-Chien; Liu Chen-Hua; Lee Mei-Hsuan; Liu Chun-Jen; Dai Chia-Yen; Chuang Wan-Long; Lin Han-Chieh; Kao Jia-Horng; Yu Ming-Lung; TACR investigators2022
Long-term effect of hcv eradication with direct acting antiviral (daas) therapy on egyptian patients with mixed cryglobulinemias (mc)Elnadry, M; Mohamed, SF; Abdelhalem, MM; Elnoomany, K2021
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort.Kondili Loreta A; Monti Monica; Quaranta Maria Giovanna; Gragnani Laura; Panetta Valentina; Brancaccio Giuseppina; Mazzaro Cesare; Persico Marcello; Masarone Mario; Gentile Ivan; Andreone Pietro; Madonia Salvatore; Biliotti Elisa; Filomia Roberto; Puoti Massimo; Fracanzani Anna Ludovica; Laccabue Diletta; Ieluzzi Donatella; Coppola Carmine; Rumi Maria Grazia; Benedetti Antonio; Verucchi Gabriella; Coco Barbara; Chemello Liliana; Iannone Andrea; Ciancio Alessia; Russo Francesco Paolo; Barbaro Francesco; Morisco Filomena; Chessa Luchino; Massari Marco; Blanc Pierluigi; Zignego Anna Linda2021
One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial.Sise Meghan Elizabeth; Goldberg David Seth; Schaubel Douglas Earl; Fontana Robert J; Kort Jens J; Alloway Rita R; Durand Christine M; Blumberg Emily A; Woodle E Steve; Sherman Kenneth E; Brown Robert S; Friedewald John J; Desai Niraj M; Sultan Samuel T; Levitsky Josh; Lee Meghan D; Strohbehn Ian A; Landis J Richard; Fernando Melissa; Gustafson Jenna L; Chung Raymond T; Reese Peter Philip2022
Relapse of HCV-Cryoglobulinemic Vasculitis Following Sustained Viral Response after Interferon-free Direct-Acting Antivirals.Fayed Ahmed; Hegazy Mohamed Tharwat; Biard Lucie; Vieira Matheus; El Shabony Tarek; Saadoun David; Casato Milvia; Visentini Marcella; Ragab Gaafar; Cacoub Patrice2022
Impact of direct acting antivirals on hepatitis C virus-related cryoglobulinemic syndrome.Zignego Anna L; Marri Silvia; Gragnani Laura2021

Downloadable Data Content

Files
  • XLSX Project Data